<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>alemtuzumab versus interferon beta 1a for relapsing‐remitting multiple sclerosis - Zhang, J - 2017 | Cochrane Library</title> <meta content="alemtuzumab versus interferon beta 1a for relapsing‐remitting multiple sclerosis - Zhang, J - 2017 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010968.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="alemtuzumab versus interferon beta 1a for relapsing‐remitting multiple sclerosis - Zhang, J - 2017 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010968.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD010968.pub2" name="dc.identifier" scheme="DOI"/> <meta content="alemtuzumab versus interferon beta 1a for relapsing‐remitting multiple sclerosis" name="citation_title"/> <meta content="Jian Zhang" name="citation_author"/> <meta content="The Second Affiliated Hospital, Guangxi Medical University" name="citation_author_institution"/> <meta content="Shengliang Shi" name="citation_author"/> <meta content="The Second Affiliated Hospital, Guangxi Medical University" name="citation_author_institution"/> <meta content="ssl_1964@163.com" name="citation_author_email"/> <meta content="Yueling Zhang" name="citation_author"/> <meta content="The Second Affiliated Hospital, Guangxi Medical University" name="citation_author_institution"/> <meta content="Jiefeng Luo" name="citation_author"/> <meta content="The Second Affiliated Hospital, Guangxi Medical University" name="citation_author_institution"/> <meta content="Yousheng Xiao" name="citation_author"/> <meta content="The First Affiliated Hospital, Guangxi Medical University" name="citation_author_institution"/> <meta content="Lian Meng" name="citation_author"/> <meta content="The First Affiliated Hospital, Guangxi University of Science and Technology" name="citation_author_institution"/> <meta content="Xiaobo Yang" name="citation_author"/> <meta content="Guangxi Medical University" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="11" name="citation_issue"/> <meta content="10.1002/14651858.CD010968.pub2" name="citation_doi"/> <meta content="2017" name="citation_date"/> <meta content="2017/11/27" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010968.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010968.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010968.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Adjuvants, Immunologic [*administration &amp; dosage, adverse effects]; Alemtuzumab [*administration &amp; dosage, adverse effects]; Disease Progression; Drug Administration Schedule; Interferon beta‐1a [*administration &amp; dosage, adverse effects]; Multiple Sclerosis, Relapsing‐Remitting [*drug therapy]; Randomized Controlled Trials as Topic; Recurrence" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010968.pub2&amp;doi=10.1002/14651858.CD010968.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010968.pub2&amp;doi=10.1002/14651858.CD010968.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010968.pub2&amp;doi=10.1002/14651858.CD010968.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010968.pub2&amp;doi=10.1002/14651858.CD010968.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010968.pub2&amp;doi=10.1002/14651858.CD010968.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010968.pub2&amp;doi=10.1002/14651858.CD010968.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010968.pub2&amp;doi=10.1002/14651858.CD010968.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010968.pub2&amp;doi=10.1002/14651858.CD010968.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010968.pub2&amp;doi=10.1002/14651858.CD010968.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010968.pub2&amp;doi=10.1002/14651858.CD010968.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010968.pub2&amp;doi=10.1002/14651858.CD010968.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010968.pub2&amp;doi=10.1002/14651858.CD010968.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010968.pub2&amp;doi=10.1002/14651858.CD010968.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010968.pub2&amp;doi=10.1002/14651858.CD010968.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010968.pub2&amp;doi=10.1002/14651858.CD010968.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010968.pub2&amp;doi=10.1002/14651858.CD010968.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010968.pub2&amp;doi=10.1002/14651858.CD010968.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010968.pub2&amp;doi=10.1002/14651858.CD010968.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010968.pub2&amp;doi=10.1002/14651858.CD010968.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010968.pub2&amp;doi=10.1002/14651858.CD010968.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010968.pub2&amp;doi=10.1002/14651858.CD010968.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010968.pub2&amp;doi=10.1002/14651858.CD010968.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010968.pub2&amp;doi=10.1002/14651858.CD010968.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="urvLIhM4";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD010968\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD010968\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010968\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010968\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","fr","de","ms","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD010968.pub2",title:"alemtuzumab versus interferon beta 1a for relapsing\\u2010remitting multiple sclerosis",firstPublishedDate:"Nov 27, 2017 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Multiple Sclerosis and Rare Diseases of the CNS Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=urvLIhM4&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010968.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD010968.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD010968.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD010968.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010968.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD010968.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD010968.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD010968.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD010968.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD010968.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Abstract&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Zusammenfassung in einfacher Sprache&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Plain language summary&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD010968.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD010968.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD010968.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD010968.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>2312 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD010968.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010968.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010968.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010968.pub2/full#CD010968-abs-0005"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010968.pub2/full#CD010968-sec-0085"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010968.pub2/full#CD010968-sec-0029"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010968.pub2/full#CD010968-sec-0030"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010968.pub2/full#CD010968-sec-0035"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010968.pub2/full#CD010968-sec-0036"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010968.pub2/full#CD010968-sec-0059"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010968.pub2/full#CD010968-sec-0079"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD010968.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010968.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010968.pub2/appendices#CD010968-sec-0090"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010968.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010968.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD010968.pub2/media/CDSR/CD010968/table_n/CD010968StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD010968.pub2/media/CDSR/CD010968/table_n/CD010968StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010968.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010968.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010968.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD010968.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD010968.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD010968.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2018 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD010968.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">alemtuzumab versus interferon beta 1a for relapsing‐remitting multiple sclerosis</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010968.pub2/information#CD010968-cr-0002">Jian Zhang</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010968.pub2/information#CD010968-cr-0003"><i class="icon corresponding-author fa fa-envelope"></i>Shengliang Shi</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010968.pub2/information#CD010968-cr-0004">Yueling Zhang</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010968.pub2/information#CD010968-cr-0005">Jiefeng Luo</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010968.pub2/information#CD010968-cr-0006">Yousheng Xiao</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010968.pub2/information#CD010968-cr-0007">Lian Meng</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010968.pub2/information#CD010968-cr-0008">Xiaobo Yang</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD010968.pub2/information/en#CD010968-sec-0095">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 27 November 2017 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD010968.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD010968.pub2">https://doi.org/10.1002/14651858.CD010968.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD010968-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010968-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD010968-abs-0004">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD010968-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD010968-abs-0003">Français</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD010968-abs-0002">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD010968-abs-0001" lang="en"> <section id="CD010968-sec-0001"> <h3 class="title" id="CD010968-sec-0001">Background</h3> <p>Alemtuzumab is a humanised monoclonal antibody that alters the circulating lymphocyte pool, causing prolonged lymphopenia, thus remoulding the immune repertoire that accompanies homeostatic lymphocyte reconstitution. It has been proved more effective than interferon (IFN) 1a for the treatment of relapsing‐remitting multiple sclerosis (RRMS). </p> </section> <section id="CD010968-sec-0002"> <h3 class="title" id="CD010968-sec-0002">Objectives</h3> <p>To compare the efficacy, tolerability and safety of alemtuzumab versus interferon beta 1a in the treatment of people with RRMS to prevent disease activity. </p> </section> <section id="CD010968-sec-0003"> <h3 class="title" id="CD010968-sec-0003">Search methods</h3> <p>We searched the Cochrane Multiple Sclerosis and Rare Diseases of the CNS Group Trials Register (1 February 2017) which, among other sources, contains records from CENTRAL, MEDLINE, Embase, CINAHL, LILACS, PEDRO and the trial registry databases Clinical Trials.gov and WHO International Clinical Trials Registry Platform for all prospectively registered and ongoing trials. </p> </section> <section id="CD010968-sec-0004"> <h3 class="title" id="CD010968-sec-0004">Selection criteria</h3> <p>All double‐blind, randomised, controlled trials comparing intravenous alemtuzumab (12 mg per day or 24 mg per day on five consecutive days during the first month and on three consecutive days at months 12, 24, 36) versus subcutaneous IFN beta 1a (Rebif), 22 μg or 44 μg three times per week, or IFN beta 1a (Avonex) by intramuscular injection 30 μg once a week, in people of any gender and age with RRMS. </p> </section> <section id="CD010968-sec-0005"> <h3 class="title" id="CD010968-sec-0005">Data collection and analysis</h3> <p>We used standard methodological procedures expected by Cochrane.</p> </section> <section id="CD010968-sec-0006"> <h3 class="title" id="CD010968-sec-0006">Main results</h3> <p>We included three trials involving 1694 participants. All trials compared alemtuzumab 12 mg per day or 24 mg per day versus IFN beta 1a for treating RRMS. In CAMMS223, participants received either subcutaneous IFN beta 1a 44 μg three times per week or annual intravenous cycles of alemtuzumab (at a dose of 12 mg per day or 24 mg per day) for 36 months. In CARE‐MS I and CARE‐MS II, participants received subcutaneous IFN beta 1a 44 μg three times per week or annual intravenous cycles of alemtuzumab 12 mg per day for 24 months. All three studies were at risk of performance bias and attrition bias, one study was 'unclear' risk in selection bias. </p> <p>Compared with interferon beta 1a, alemtuzumab given at a dose of 12 mg per day probably reduces the risk of relapse (risk ratio (RR) 0.60, 95% confidence interval (CI) 0.52 to 0.70, moderate quality evidence), may reduce the risk of worsening disability (RR 0.60, 95% CI 0.45 to 0.79, low quality evidence) and the risk of developing new T2 lesions on magnetic resonance imaging (RR 0.75, 95% CI 0.61 to 0.93, low quality evidence) after 24 and 36 months' follow‐up. Mean Expanded Disability Status Scale (EDSS) scores may be similar between the treatment regimens (mean difference (MD) ‐0.35, 95% CI ‐0.73 to 0.03, low quality evidence). </p> <p>At a dose of 24 mg per day alemtuzumab may reduce relapse (RR 0.38, 95% CI 0.23 to 0.62, low quality evidence), worsening disability (RR 0.42, 95% CI 0.21 to 0.84, low quality evidence). The effects on EDSS scores when compared with interferon beta 1a at three years are uncertain due to the very low quality of evidence (MD ‐0.83, 95% CI ‐1.17 to ‐0.49). </p> <p>All three trials reported adverse events and serious adverse events. The risk of experiencing an adverse event in either alemtuzumab 12 mg or interferon groups may be similar (RR 1.03, 95% CI 0.98 to 1.08, low quality evidence). The risk of serious adverse events is probably similar between treatments (RR 1.03, 95% CI 0.82 to 1.29, moderate quality evidence). The risk of any adverse event may be similar between alemtuzumab 24 mg and interferon (RR 1.02, 95% CI 0.96 to 1.08, low quality evidence). The risk of serious adverse events is probably similar between treatments (RR 0.95, 95% CI 0.70 to 1.31, moderate quality evidence). </p> </section> <section id="CD010968-sec-0007"> <h3 class="title" id="CD010968-sec-0007">Authors' conclusions</h3> <p>Annual intravenous cycles of alemtuzumab at a dose of 12 mg per day probably reduces the proportion of participants who experience relapse, may reduce the proportion of participants who experience disability worsening and development of new T2 lesions on MRI over 2 to 3 years in comparison with subcutaneous IFN beta‐1a 44 μg three times per week. Annual intravenous cycles of alemtuzumab at a dose of 24 mg per day may reduce the proportion of participants who experience relapse and disability worsening over 3 years in comparison with subcutaneous IFN beta‐1a 44 μg three times per week. An average reduction of 0.8 EDSS units with alemtuzumab compared with interferon beta‐1a was observed at a dose of 24 mg per day in one study. </p> <p>The rates of adverse events were similarly high for both treatments. The most frequently reported adverse events for both treatments were infusion‐associated reactions, infections and autoimmune events. The use of alemtuzumab requires careful monitoring so that potentially serious adverse events can be treated early and effectively. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD010968-abs-0005" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010968-abs-0005">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD010968-abs-0009">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD010968-abs-0008">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD010968-abs-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD010968-abs-0007">Français</a> </li> <li class="section-language"> <a class="" href="full/ms#CD010968-abs-0010">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD010968-abs-0006">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD010968-abs-0005" lang="en"> <h3>Alemtuzumab, a humanised monoclonal antibody, as possible alternative therapy to interferon beta 1a in people with RRMS </h3> <p><b>Background</b> </p> <p>Multiple sclerosis is a progressive disease of the central nervous system where the person's own body destroys the coating that protects nerves. The disease may go into remission (where the symptoms reduce or stop) and then relapse (where the symptoms return). This is called relapsing‐remitting multiple sclerosis (RRMS). Medicines called monoclonal antibodies (such as alemtuzumab) could be a possible alternative immunotherapy (treatment to stimulate the immune system) to interferon beta treatment (one of the usual treatments) in people with RRMS. In this review, we aimed to compare the benefits, side effects and safety of alemtuzumab versus interferon beta 1a in the treatment of people with RRMS. </p> <p><b>Study characteristics</b> </p> <p>We searched medical databases and found three studies involving 1694 participants (CAMMS223, CARE‐MS I and CARE‐MS II). CAMMS223 involved people with previously untreated, early RRMS. Participants received either subcutaneous (under the skin) interferon beta 1a (at a dose of 44 μg) three times per week or annual intravenous (into a vein) courses of alemtuzumab (at a dose of either 12 mg per day or 24 mg per day) for 36 months. CARE‐MS I enrolled adults aged 18 to 50 years with previously untreated RRMS. Participants received annual intravenous courses of alemtuzumab 12 mg per day or subcutaneous interferon beta 1a 44 μg three times per week for 24 months. CARE‐MS II enrolled adults aged 18 to 55 years with RRMS and at least one relapse while on interferon beta or glatiramer (another medicine that alters the immune response) treatment. Participants received subcutaneous interferon beta 1a 44 μg three times per week, annual intravenous courses of alemtuzumab 12 mg per day or annual intravenous courses of alemtuzumab 24 mg per day for 24 months. The evidence is current to 1 February 2017. </p> <p><b>Key results</b> </p> <p>The review of trials found that, compared with subcutaneous interferon beta 1a three times per week, annual intravenous cycles of alemtuzumab probably reduces the proportion of participants who experience relapse, may reduce the proportion of participants who experience disability worsening and development of new T2 lesions on MRI. In one study, alemtuzumab 24 mg leads to slightly better EDSS scores when compared with interferon beta 1a. </p> <p>The rates of adverse events were similarly high for both treatments. The most frequently reported adverse events for both treatments were infusion‐associated reactions, infections and autoimmune events. The use of alemtuzumab requires careful monitoring so that potentially serious adverse events can be treated early and effectively. </p> <p><b>Quality of the evidence</b> </p> <p>The quality of the body of evidence obtained for each outcome is mainly low except for the number of participants experiencing at least one relapse for which the quality of evidence was moderate. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD010968-sec-0085" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD010968-sec-0085"></div> <h3 class="title" id="CD010968-sec-0086">Implications for practice</h3> <section id="CD010968-sec-0086"> <p>Annual intravenous cycles of alemtuzumab at a dose of 12 mg per day probably reduces the proportion of participants who experience relapse, may reduce the proportion of participants who experience disability worsening and development of new T2 lesions on MRI over 2 to 3 years in comparison with subcutaneous IFN beta‐1a 44 μg three times per week. Annual intravenous cycles of alemtuzumab at a dose of 24 mg per day may reduce the proportion of participants who experience relapse and disability worsening over 3 years in comparison with subcutaneous IFN beta‐1a 44 μg three times per week. An average reduction of 0.8 EDSS units with alemtuzumab compared with interferon beta‐1a was observed at a dose of 24 mg per day in one study. </p> <p>The rates of adverse events were similarly high for both treatments. The most frequently reported adverse events for both treatments were infusion‐associated reactions, infections and autoimmune events. The use of alemtuzumab requires careful monitoring so that potentially serious adverse events can be treated early and effectively. </p> </section> <h3 class="title" id="CD010968-sec-0087">Implications for research</h3> <section id="CD010968-sec-0087"> <p>Future well‐designed randomised, double‐blind, controlled trials with larger sample sizes either for mono or combination therapy with alemtuzumab in RRMS are needed. Health‐related quality of life outcome should be addressed for such a disabling disease in future research. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD010968-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD010968-sec-0029"></div> <div class="table" id="CD010968-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Alemtuzumab 12 mg compared to interferon beta 1a for relapsing‐remitting multiple sclerosis</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>alemtuzumab<b>12 mg compared to interferon beta 1a for relapsing‐remitting multiple sclerosis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with relapsing‐remitting multiple sclerosis<br/> <b>Settings:</b> <br/> <b>Intervention:</b> alemtuzumab 12 mg<br/> <b>Comparison:</b> interferon beta 1a </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Interferon beta 1a</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>alemtuzumab12 mg</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants experiencing at least one relapse</b><br/> Follow‐up: 24‐36 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>448 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>269 per 1000</b><br/> (233 to 314) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.6</b> <br/> (0.52 to 0.70) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1414<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants whose disability worsened</b><br/> Follow‐up: 24‐36 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>168 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>101 per 1000</b><br/> (76 to 133) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.6</b> <br/> (0.45 to 0.79) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1414<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1<b>,</b>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants with at least one adverse event</b><br/> Follow‐up: 24‐36 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>948 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>976 per 1000</b><br/> (929 to 1000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.03</b><br/> (0.98 to 1.08) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1415<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants with serious adverse events</b><br/> Follow‐up: 24‐36 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>192 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>197 per 1000</b><br/> (157 to 247) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.03</b> <br/> (0.82 to 1.29) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1415<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean Expanded Disability Status Scale score change from baseline</b> <br/> Follow‐up: 24‐36 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean EDSS score in the control groups ranged from <b>‐0.14 to 0.38</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean EDSS score in the intervention groups was <b>0.35 lower</b> (0.73 lower to 0.03 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1414<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants with new T2‐hyperintense lesions on magnetic resonance imaging</b><br/> Follow‐up: 24 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>630 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>472 per 1000</b><br/> (384 to 585) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.75</b><br/> (0.61 to 0.93) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1125<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants experiencing treatment discontinuation caused by adverse events</b><br/> Follow‐up: 24‐36 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>76 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>25 per 1000</b><br/> (14 to 43) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.33</b><br/> (0.19 to 0.56) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1414<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). The assumed risk in the comparison group is the median control group risk across studies. </p> <p>CI: Confidence interval; RR: Risk ratio.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded one level due to study limitation (blinding of participants and personnel could not be well performed). </p> <p><sup>2</sup> Downgraded for one level due to inconsistency (I<sup>2</sup> = 66%)<br/> <sup>3</sup> Downgraded for one level due to inconsistency (I<sup>2</sup> = 85%)<br/> <sup>4</sup> Downgraded one level due to inconsistency (high heterogeneity, I<sup>2</sup> = 88%)<br/> <sup>5</sup> Downgraded one level due to inconsistency (high heterogeneity, I<sup>2</sup> = 73%).<br/> <sup>6</sup>Downgraded one level due to imprecision (low number of events). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD010968-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Alemtuzumab 24 mg compared to interferon beta 1a for relapsing‐remitting multiple sclerosis</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>alemtuzumab<b>24 mg compared to interferon beta 1a for relapsing‐remitting multiple sclerosis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with relapsing‐remitting multiple sclerosis<br/> <b>Settings:</b> <br/> <b>Intervention:</b> alemtuzumab 24 mg<br/> <b>Comparison:</b> interferon beta 1a </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Interferon beta 1a</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>alemtuzumab24 mg</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants experiencing at least one relapse</b><br/> Follow‐up: 36 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>405 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>154 per 1000</b><br/> (93 to 251) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.38</b> <br/> (0.23 to 0.62) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>221<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single study estimate</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants whose disability worsened</b><br/> Follow‐up: 36 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>216 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>91 per 1000</b><br/> (45 to 182) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.42</b> <br/> (0.21 to 0.84) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>221<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single study estimate</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants with at least one adverse event</b><br/> Follow‐up: 24‐36 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>964 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>984 per 1000</b><br/> (926 to 1000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.02</b> <br/> (0.96 to 1.08) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>578<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants with serious adverse events</b><br/> Follow‐up: 24‐36 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>220 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>209 per 1000</b><br/> (154 to 288) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.95</b> <br/> (0.7 to 1.31) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>578<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean Expanded Disability Status Scale score change from baseline</b><br/> Follow‐up: 36 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean EDSS score in the control group was <b>0.38 higher</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean EDSS score in the intervention group was <b>0.45 lower</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>221<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single study estimate</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants experiencing treatment discontinuation caused by adverse events</b><br/> Follow‐up: 24‐36 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>89 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>30 per 1000</b><br/> (9 to 14) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.34</b> </p> <p>(0.10 to 1.16)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>593<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). The assumed risk in the comparison group is the median control group risk across studies. </p> <p>CI: Confidence interval; RR: Risk ratio.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded one level due to study limitation (blinding of participants and personnel could not be well performed). </p> <p><sup>2</sup> Downgraded one level due to imprecision (low number of events).<br/> <sup>3</sup> Downgraded one level due to inconsistency (high heterogeneity, I<sup>2</sup> = 86%.) </p> <p><sup>4</sup> Imprecision (‐2): In view of the low number of participants and the wide confidence intervals, we downgraded by two points. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD010968-sec-0030" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD010968-sec-0030"></div> <section id="CD010968-sec-0031"> <h3 class="title" id="CD010968-sec-0031">Description of the condition</h3> <p>Multiple sclerosis (MS) is an autoimmune disease of the central nervous system which is characterised by disseminated inflammatory demyelination. It mainly affects young adults, and leads to disability (<a href="./references#CD010968-bbs2-0025" title="Montalban X ,  TintoréM ,  SwantonJ ,  BarkhofF ,  FazekasF ,  FilippiM , et al. MRI criteria for MS in patients with clinically isolated syndromes. Neurology2010 ;74(5):427‐34. ">Montalban 2010</a>). It has high prevalence in western Europe and North America (more than 100 people per 100,000 population); lower prevalence in central and eastern Europe, the Balkans, Australia and New Zealand (50 per 100,000); and lowest prevalence in Asia, the Middle East, Africa and South America (about 10 to 20 per 100,000) (<a href="./references#CD010968-bbs2-0020" title="Koch‐Henriksen N ,  SørensenPS . The changing demographic pattern of multiple sclerosis epidemiology. Lancet Neurology2010 ;9(5):520‐32. ">Koch‐Henriksen 2010</a>). Women have approximately a two‐fold increased risk of developing MS than men. After the first attack, known as clinically isolated syndromes, which refers to a first episode of largely reversible neurological dysfunction with features suggestive of MS, 51% of people develop MS within six years (<a href="./references#CD010968-bbs2-0007" title="ChardDT ,  DaltonCM ,  SwantonJ ,  FisnikuLK ,  MiszkielKA ,  ThompsonAJ ,  etal . MRI only conversion to multiple sclerosis following a clinically isolated syndrome. Journal of Neurology, Neurosurgery &amp; Psychiatry2011;82(2):176‐9. ">Chard 2011</a>; <a href="./references#CD010968-bbs2-0024" title="MillerDH , ChardDT , CiccarelliO . Clinically isolated syndromes. Lancet Neurology2012;11(2):157‐69. ">Miller 2012</a>). Most people with MS have a relapsing‐remitting course, but after 10 years over half of people with MS convert to a secondary progressive phase which is characterised by continuing deterioration without remission (<a href="./references#CD010968-bbs2-0039" title="Weinshenker BG ,  BassB ,  RiceGP ,  NoseworthyJ ,  CarriereW ,  BaskervilleJ ,  etal . The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain1989;112:133‐46. ">Weinshenker 1989</a>). </p> <p>Magnetic resonance imaging (MRI) provides a reflection of the underlying pathology. The MRI measures of disease activity (enhancing demyelinating lesions) and severity (T2‐T1‐weighted lesion burden) are used to monitor the natural evolution of the disease and treatment effects. They have been integrated with clinical data into diagnostic criteria for MS (<a href="./references#CD010968-bbs2-0023" title="McDonaldWI , CompstonA , EdanG , GoodkinD , HartungHP , LublinFD , et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Annals of Neurology2001;50(1):121‐7. ">McDonald 2001</a>; <a href="./references#CD010968-bbs2-0028" title='PolmanCH , ReingoldSC , EdanG , FilippiM , HartungHP , KapposL , et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Annals of Neurology2005;58(6):840‐6. '>Polman 2005</a>; <a href="./references#CD010968-bbs2-0029" title="PolmanCH , ReingoldSC , BanwellB , ClanetM , CohenJA , FilippiM , et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Annals of Neurology2011;69(2):292‐302. ">Polman 2011</a>). </p> <p>Considering the autoimmune pathogenesis of the disease, the mainstay of treatment is immunomodulatory therapy with interferon (IFN) beta and glatiramer acetate (GA), which are the current standard first‐line treatments for MS. They reduce relapse frequency by about 30% (<a href="./references#CD010968-bbs2-0006" title="BrownJW , ColesAJ . Alemtuzumab: evidence for its potential in relapsing‐remitting multiple sclerosis. Drug Design, Development and Therapy2013;7:131‐8. ">Brown 2013</a>). Natalizumab, and more recently, fingolimod, have been introduced for people with highly active disease; they are more efficacious but have a more problematic safety profile than IFN and GA (<a href="./references#CD010968-bbs2-0006" title="BrownJW , ColesAJ . Alemtuzumab: evidence for its potential in relapsing‐remitting multiple sclerosis. Drug Design, Development and Therapy2013;7:131‐8. ">Brown 2013</a>; <a href="./references#CD010968-bbs2-0032" title="PucciE , GiulianiG , SolariA , SimiS , MinozziS , DiPietrantonjC , et al. Natalizumab for relapsing remitting multiple sclerosis. Cochrane Database of Systematic Reviews2011, Issue 10. [DOI: 10.1002/14651858.CD007621] ">Pucci 2011</a>). </p> <p>The social costs associated with MS are high because of its long duration, the early loss of productivity, the need for assistance in activities of daily living, and the use of immunomodulatory treatments and multi‐disciplinary health care (<a href="./references#CD010968-bbs2-0021" title="KoutsourakiE ,  CostaV ,  BaloyannisS . Epidemiology of multiple sclerosis in Europe: a review. International Review of Psychiatry2010;22(1):2‐13. ">Koutsouraki 2010</a>). </p> </section> <section id="CD010968-sec-0032"> <h3 class="title" id="CD010968-sec-0032">Description of the intervention</h3> <p>IFN beta 1a is a lyophilised glycoprotein produced in mammalian cells using the natural human gene sequence. Two preparations are licensed for the treatment of MS: 30 μg once a week administered by intramuscular injection (Avonex) and 22 μg or 44 μg administered three times a week by subcutaneous injections (Rebif). Their efficacy on disease activity is partial (<a href="./references#CD010968-bbs2-0006" title="BrownJW , ColesAJ . Alemtuzumab: evidence for its potential in relapsing‐remitting multiple sclerosis. Drug Design, Development and Therapy2013;7:131‐8. ">Brown 2013</a>). IFN therapy has been associated with a high frequency of treatment‐related adverse events, mainly influenza‐like reactions and injection site reactions; most people treated with IFN have leukopenia, lymphopenia, thrombocytopenia and increased plasma hepatic enzymes (<a href="./references#CD010968-bbs2-0034" title="RiceGP , IncorvaiaB , MunariL , EbersG , PolmanC , D'AmicoR , et al. Interferon in relapsing‐remitting multiple sclerosis. Cochrane Database of Systematic Reviews2001, Issue 4. [DOI: 10.1002/14651858.CD002002] ">Rice 2001</a>). These data suggest the need for alternative MS treatments with less invasive routes of administration and new modes of action to expand the current treatment repertoire, increase patient satisfaction and adherence, and thereby improve efﬁcacy. </p> <p>alemtuzumab is a humanised monoclonal antibody (mAb), approved by the US Food and Drug Administration (FDA) for the treatment of B‐cell chronic lymphocytic leukaemia (<a href="./references#CD010968-bbs2-0013" title="USFood , DrugAdministration . Compath (alemtuzumab) intravenous product approval information ‐ licensing action 2000. www.accessdata.fda.gov/drugsatfda_docs/nda/2000/103948s000_CampathTOC.cfm(accessed October 2017). ">FDA 2000</a>). It binds to CD52, a 12‐amino acid cell surface protein (<a href="./references#CD010968-bbs2-0016" title="HaleG . The CD52 antigen and development of the CAMPATH antibodies. Cytotherapy2001;3(3):137‐43. ">Hale 2001</a>) that is expressed at high levels on T cells and B cells, and at lower levels on monocytes, macrophages and eosinophils. Cells of the innate immune system are unaffected (<a href="./references#CD010968-bbs2-0008" title="ColesAJ . Alemtuzumab therapy for multiple sclerosis. Neurotherapeutics2013;10(1):29‐33. ">Coles 2013</a>). alemtuzumab alters the circulating lymphocyte pool (<a href="./references#CD010968-bbs2-0009" title="CukerA ,  ColesAJ ,  SullivanH ,  FoxE ,  GoldbergM ,  OyuelaP ,  etal . A distinctive form of immune thrombocytopenia in a phase 2 study of alemtuzumab for the treatment of relapsing‐remitting multiple sclerosis. Blood2011;118(24):6299‐305. ">Cuker 2011</a>), causing prolonged lymphopenia (<a href="./references#CD010968-bbs2-0037" title="ThompsonSA ,  JonesJL ,  CoxAL ,  CompstonDA ,  ColesAJ . B‐cell reconstitution and BAFF after alemtuzumab (Campath‐1H) treatment of multiple sclerosis. Journal of Clinical Immunology2010;30(1):99‐105. ">Thompson 2010</a>). The therapeutic effect of alemtuzumab is mediated by the remoulding of the immune repertoire that accompanies homeostatic lymphocyte reconstitution (<a href="./references#CD010968-bbs2-0008" title="ColesAJ . Alemtuzumab therapy for multiple sclerosis. Neurotherapeutics2013;10(1):29‐33. ">Coles 2013</a>). Recovery of B and T lymphocytes to the lower limit of normal after a single course of alemtuzumab takes eight months (B lymphocytes) and three years (T lymphocytes) (<a href="./references#CD010968-bbs2-0019" title="Hill‐CawthorneGA , ButtonT , TuohyO , JonesJL , MayK , SomerfieldJ , et al. Long term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis. Journal of Neurology, Neurosurgery &amp; Psychiatry2012;83(3):298‐304. ">Hill‐Cawthorne 2012</a>). alemtuzumab is given as an intravenous infusion of 12 mg/day on five consecutive days during the first month (first cycle) and on three consecutive days at months 12 (second cycle) and 24 (third cycle). </p> <p>For people with secondary progressive MS, alemtuzumab significantly reduces the mean relapse rate and the risk of new MRI lesions. However, the person's disability continues to deteriorate as their cerebral atrophy progresses. For people with relapsing‐remitting MS (RRMS), unlike the progressive cohort, mean disability scores decrease after alemtuzumab (<a href="./references#CD010968-bbs2-0008" title="ColesAJ . Alemtuzumab therapy for multiple sclerosis. Neurotherapeutics2013;10(1):29‐33. ">Coles 2013</a>). In a unique programme of drug development in MS, alemtuzumab has been compared in one phase II trial and two phase III trials with the active comparator IFN beta 1a. In these trials, alemtuzumab was more effective in suppressing relapses compared to IFN beta 1a. Indeed, alemtuzumab treatment led to an improvement in disability and a reduction in cerebral atrophy (<a href="./references#CD010968-bbs2-0008" title="ColesAJ . Alemtuzumab therapy for multiple sclerosis. Neurotherapeutics2013;10(1):29‐33. ">Coles 2013</a>). </p> <p>However, alemtuzumab use was associated with an increased occurrence of autoimmune disorders, such as immune thrombocytopenia, thyroid disease and antiglomerular basement membrane disease (<a href="./references#CD010968-bbs2-0009" title="CukerA ,  ColesAJ ,  SullivanH ,  FoxE ,  GoldbergM ,  OyuelaP ,  etal . A distinctive form of immune thrombocytopenia in a phase 2 study of alemtuzumab for the treatment of relapsing‐remitting multiple sclerosis. Blood2011;118(24):6299‐305. ">Cuker 2011</a>). Moreover, in 2005, three people with MS developed severe idiopathic thrombocytopenic purpura while participating in a clinical study of alemtuzumab (Campath) (<a href="./references#CD010968-bbs2-0014" title="USFood , DrugAdministration . Alemtuzumab (marketed as Campath) information. www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm082681.htm(accessed October 2017). ">FDA 2005</a>). One of these people died. </p> </section> <section id="CD010968-sec-0033"> <h3 class="title" id="CD010968-sec-0033">How the intervention might work</h3> <p>The pathology of MS suggests an autoimmune aetiology and includes infiltration of T cells, B cells and macrophages in active MS brain lesions (<a href="./references#CD010968-bbs2-0026" title="OdeFJr , MooreCS , KennedyTE , AntelJP , Bar‐OrA , DhaunchakAS . MicroRNA dysregulation in multiple sclerosis. Frontiers in Genetics2012;3:311. ">Ode 2012</a>). alemtuzumab causes rapid and prolonged lymphocyte depletion, finally resulting in immunosuppression and decreased central nervous system immunosurveillance (<a href="./references#CD010968-bbs2-0005" title="BielekovaB , BeckerBL . Monoclonal antibodies in MS: mechanisms of action. Neurology2010;74 Suppl 1:31‐40. ">Bielekova 2010</a>). After alemtuzumab therapy, the consequent homeostatic reconstitution leads to a radically reformed lymphocyte pool with a relative increase in regulatory T cells and expansion of autoreactive T cells (<a href="./references#CD010968-bbs2-0008" title="ColesAJ . Alemtuzumab therapy for multiple sclerosis. Neurotherapeutics2013;10(1):29‐33. ">Coles 2013</a>). In theory, these repertoire changes induced by alemtuzumab may improve long‐term efficacy, but it could also underlie development of antibody‐mediated autoimmune complications (<a href="./references#CD010968-bbs2-0005" title="BielekovaB , BeckerBL . Monoclonal antibodies in MS: mechanisms of action. Neurology2010;74 Suppl 1:31‐40. ">Bielekova 2010</a>). </p> <p>Studies have demonstrated the efficacy of IFN beta 1a in people with RRMS (<a href="./references#CD010968-bbs2-0027" title="PanitchH , GoodinDS , FrancisG , ChangP , CoylePK , O'ConnorP , et al. Randomized, comparative study of interferon beta‐1a treatment regimens in MS: the EVIDENCE trial. Neurology2002;59(10):1496‐506. ">Panitch 2002</a>; <a href="./references#CD010968-bbs2-0031" title="PRISMS (Prevention of Relapses and Disability by Interferon β‐1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double‐blind placebo‐controlled study of interferon β‐1a in relapsing/remitting multiple sclerosis. Lancet1998;352(9139):1498‐504. ">PRISMS 1998</a>; <a href="./references#CD010968-bbs2-0036" title="SchwidSR , PanitchHS . Full results of the Evidence of Interferon Dose‐Response‐European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor‐blinded comparison of low‐dose weekly versus high‐dose, high‐frequency interferon beta‐1a for relapsing multiple sclerosis. Clinical Therapeutics2007;29(9):2031‐48. ">Schwid 2007</a>), and it has been commonly used in clinical practice. The mechanism of action of these therapeutic agents remains undefined. Several modes of action have been proposed, including: inhibition of T‐cell activation and proliferation; apoptosis of autoreactive T cells; induction of regulatory T cells; inhibition of leukocyte migration across the blood‐brain barrier; cytokine modulation and potential antiviral activity. Endogenously produced IFN in the injured brain is also now believed to contribute to mediation of anti‐inflammatory and regenerative effects (<a href="./references#CD010968-bbs2-0010" title="Dhib‐JalbutS . Mechanisms of action of interferons and glatiramer acetate in multiple sclerosis. Neurology2002;58 Suppl 4(8):3‐9. ">Dhib‐Jalbut 2002</a>; <a href="./references#CD010968-bbs2-0011" title="Dhib‐JalbutS , MarksS . Interferon‐beta mechanisms of action in multiple sclerosis. Neurology2010;74 Suppl 1:17‐24. ">Dhib‐Jalbut 2010</a>). </p> </section> <section id="CD010968-sec-0034"> <h3 class="title" id="CD010968-sec-0034">Why it is important to do this review</h3> <p>mAbs have gained relevance in the treatment of MS. Trials demonstrated that alemtuzumab is more effective than IFN beta 1a, significantly reducing the relapse rate, risk for sustained accumulation of disability and mean Expanded Disability Status Scale (EDSS) score at month 36 after treatment. However, 30% of people develop autoimmunity (<a href="./references#CD010968-bbs2-0037" title="ThompsonSA ,  JonesJL ,  CoxAL ,  CompstonDA ,  ColesAJ . B‐cell reconstitution and BAFF after alemtuzumab (Campath‐1H) treatment of multiple sclerosis. Journal of Clinical Immunology2010;30(1):99‐105. ">Thompson 2010</a>). Marketing authorisation for alemtuzumab has been filed, and whilst trial data suggest that its efficacy outperforms both licensed drugs and others in development, there is a significant risk of adverse events, such as infusion‐associated reactions, mild‐to‐moderate infections and autoimmunity (<a href="./references#CD010968-bbs2-0004" title="AliR , NicholasRS , MuraroPA . Drugs in development for relapsing multiple sclerosis. Drugs2013;73(7):625‐50. ">Ali 2013</a>; <a href="./references#CD010968-bbs2-0008" title="ColesAJ . Alemtuzumab therapy for multiple sclerosis. Neurotherapeutics2013;10(1):29‐33. ">Coles 2013</a>). While the European Medicines Agency (EMA) has already approved it for RRMS (<a href="./references#CD010968-bbs2-0012" title="European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP) summary of opinion (initial authorisation) Lemtrada (alemtuzumab). www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_‐_Initial_authorisation/human/003718/WC500144904.pdf(accessed October 2017). ">EMA 2013</a>), it has not been approved by the FDA (<a href="./references#CD010968-bbs2-0015" title="USFood , DrugAdministration . Peripheral and Central Nervous System Drugs Advisory committee meeting ‐ alemtuzumab (BLA 103948\5139) background package. www.accessdata.fda.gov/drugsatfda_docs/appletter/2014/103948orig1s5139ltr.pdf(accessed October 2017). ">FDA 2013</a>; <a href="./references#CD010968-bbs2-0038" title="ThompsonAJ ,  GiovannoniG . Removal of access to alemtuzumab for patients with aggressive multiple sclerosis. BMJ2013;346:275. ">Thompson 2013</a>). </p> <p>A systematic review is warranted to assess the efficacy, tolerability and safety profile of alemtuzumab versus IFN beta 1a. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD010968-sec-0035" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD010968-sec-0035"></div> <p>To compare the benefit, tolerability and safety of alemtuzumab versus IFN beta 1a in the treatment of people with RRMS to prevent disease activity. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD010968-sec-0036" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD010968-sec-0036"></div> <section id="CD010968-sec-0037"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD010968-sec-0038"> <h4 class="title">Types of studies</h4> <p>Double‐blind, randomised, controlled trials (RCTs). We excluded uncontrolled, non‐randomised and quasi‐randomised trials. </p> </section> <section id="CD010968-sec-0039"> <h4 class="title">Types of participants</h4> <p>We included participants of any gender and age with RRMS fulfilling Poser criteria (<a href="./references#CD010968-bbs2-0030" title="PoserCM , PatyDW , ScheinbergL , McDonaldWI , DavisFA , EbersGC , et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Annals of Neurology1983;13(3):227‐31. ">Poser 1983</a>), or original or revised McDonald criteria (<a href="./references#CD010968-bbs2-0023" title="McDonaldWI , CompstonA , EdanG , GoodkinD , HartungHP , LublinFD , et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Annals of Neurology2001;50(1):121‐7. ">McDonald 2001</a>; <a href="./references#CD010968-bbs2-0028" title='PolmanCH , ReingoldSC , EdanG , FilippiM , HartungHP , KapposL , et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Annals of Neurology2005;58(6):840‐6. '>Polman 2005</a>; <a href="./references#CD010968-bbs2-0029" title="PolmanCH , ReingoldSC , BanwellB , ClanetM , CohenJA , FilippiM , et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Annals of Neurology2011;69(2):292‐302. ">Polman 2011</a>). We excluded participants with: a progressive disease course; previous immunosuppressive, investigational or monoclonal antiboby therapy and clinically significant autoimmune disorder other than MS. </p> </section> <section id="CD010968-sec-0040"> <h4 class="title">Types of interventions</h4> <p>Experimental intervention: intravenous alemtuzumab 12 mg per day or 24 mg per day on five consecutive days during the first month and on three consecutive days at months 12 and 24. </p> <p>Control intervention: subcutaneous IFN beta 1a (Rebif) 22 μg or 44 μg three times per week or intramuscular IFN beta 1a (Avonex) 30 μg once a week. </p> </section> <section id="CD010968-sec-0041"> <h4 class="title">Types of outcome measures</h4> <section id="CD010968-sec-0042"> <h5 class="title">Primary outcomes</h5> <p>Benefit:</p> <p> <ul id="CD010968-list-0001"> <li> <p>number of participants experiencing at least one relapse at 24 and 36 months. Relapse was deﬁned as new or worsening pre‐existing neurological symptoms, without fever, that lasted for 48 hours or more and that were accompanied by a change in Functional Score on Kurtzke's EDSS scale assessed by the examining physician. One or more of the following changes compared with baseline was required for relapse confirmation: an increase in total EDSS by 0.5 points; an increase of at least 1 point in two functional‐systems scores, or of at least 2 points in one functional‐system score. Other less stringent criteria were accepted. </p> </li> <li> <p>number of participants whose disability worsened at 24 and 36 months, defined as an increase of at least 1.5 points on the EDSS scale for participants with a baseline score of 0, of at least 1.0 point for participants with a baseline score of 1.0 or more, and of at least 0.5 point for participants with a baseline score of 5.5 or more, sustained for six months (<a href="./references#CD010968-bbs2-0022" title="KurtzkeJF . Rating neurologic impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS). Neurology1983;33:1444‐52. ">Kurtzke 1983</a>). </p> </li> </ul> </p> <p>Safety:</p> <p> <ul id="CD010968-list-0002"> <li> <p>number of participants with at least one adverse event, including serious adverse events. </p> </li> </ul> </p> </section> <section id="CD010968-sec-0043"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD010968-list-0003"> <li> <p>mean EDSS score change from baseline at 24 and 36 months.</p> </li> <li> <p>number of participants with new T2‐hyperintense lesions on MRI at 24 and 36 months.</p> </li> <li> <p>number of participants experiencing treatment discontinuation caused by adverse events.</p> </li> </ul> </p> </section> </section> </section> <section id="CD010968-sec-0044"> <h3 class="title">Search methods for identification of studies</h3> <p>We conducted a systematic search without language restrictions to identify all relevant published and unpublished RCTs. </p> <section id="CD010968-sec-0045"> <h4 class="title">Electronic searches</h4> <p>The Information Specialist searched the Cochrane Multiple Sclerosis and Rare Diseases of the CNS Group Trials Register, which, among other sources, contains trials from: </p> <p> <ul id="CD010968-list-0004"> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL) (2017, Issue 1);</p> </li> <li> <p>MEDLINE (PubMed) (1966 to 1 February 2017);</p> </li> <li> <p>Embase (Embase.com) (1974 to 1 February 2017);</p> </li> <li> <p>Cumulative Index to Nursing and Allied Health Literature (CINAHL) (EBSCOhost) (1981 to 1 February 2017); </p> </li> <li> <p>Latin American and Caribbean Health Science Information Database (LILACS) (Bireme) (1982 to 1 February 2017); </p> </li> <li> <p>ClinicalTrials.gov (<a href="http://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a>); </p> </li> <li> <p>World Health Organization (WHO) International Clinical Trials Registry Platform (<a href="http://apps.who.int/trialsearch" target="_blank">apps.who.int/trialsearch</a>). </p> </li> </ul> </p> <p>The keywords for this review are listed in <a href="./appendices#CD010968-sec-0091">Appendix 1</a>. </p> <p>Information on the Trials Register or the Review Group and details of the search strategies used to identify trials can be found in the 'Specialised Register' section within the Cochrane Multiple Sclerosis and Rare Diseases of the CNS Group <a href="http://onlinelibrary.wiley.com/o/cochrane/clabout/articles/MS/frame.html" target="_blank">module</a>. </p> <p>In addition, the review authors searched the following three Chinese databases using the search terms (duofaxingyinghua) AND (alundankang) AND (β‐ganraosu): </p> <p> <ul id="CD010968-list-0005"> <li> <p>China Biological Medicine Database (CBM‐disc) (1979 to 1 February 2017);</p> </li> <li> <p>Chinese National Knowledge Infrastructure Database (CNKI) (1979 to 1 February 2017);</p> </li> <li> <p>VIP Chinese Science and Technique Journals Database (1979 to 1 February 2017).</p> </li> </ul> </p> </section> <section id="CD010968-sec-0046"> <h4 class="title">Searching other resources</h4> <p>In addition, we used the following methods.</p> <p> <ul id="CD010968-list-0006"> <li> <p>We screened reference lists of relevant review articles and primary studies found.</p> </li> <li> <p>We contacted experts in the field to identify further published or unpublished trials.</p> </li> <li> <p>we handsearched congress reports and conference proceedings (from 1994 to 1 February 2017) from the most important neurological associations and MS Societies (e.g. American Academy of Neurology, American Neurological Association, American Committee for Treatment and Research in MS, the European Committee for Treatment and Research in MS) and contact pharmaceutical companies. </p> </li> </ul> </p> </section> </section> <section id="CD010968-sec-0047"> <h3 class="title" id="CD010968-sec-0047">Data collection and analysis</h3> <section id="CD010968-sec-0048"> <h4 class="title">Selection of studies</h4> <p>Three review authors (JZ, YX, JL) independently screened titles and abstracts of the citations retrieved by the literature search. We selected the full text of potentially relevant studies for further assessment. We independently evaluated the eligibility of these studies on the basis of information available in the published data. Any disagreement regarding inclusion was resolved by discussion among all review authors. </p> <p>We collated multiple reports of the same study, so that each study rather than each report, was the unit of interest in the review. </p> </section> <section id="CD010968-sec-0049"> <h4 class="title">Data extraction and management</h4> <p>Three review authors (JZ, YX, JL) independently extracted the following data.</p> <p> <ul id="CD010968-list-0007"> <li> <p>Participants: diagnostic criteria, number in each group, age, gender, baseline comparability between groups, length of follow‐up, withdrawals or losses to follow‐up. </p> </li> <li> <p>Methods: study design; randomisation method; allocation concealment method; blinding methods of participants, personnel and outcome assessors. </p> </li> <li> <p>Interventions: details of alemtuzumab and IFN beta 1a, such as administration method, dosage and duration, treatment period, cointervention(s). </p> </li> <li> <p>Outcomes: primary and secondary outcomes.</p> </li> <li> <p>Other: country and setting, publication year, sources of funding, intention‐to‐treat (ITT) analysis. </p> </li> </ul> </p> <p>Any disagreements were resolved by discussion among all the review authors.</p> </section> <section id="CD010968-sec-0050"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (JZ, JL) independently assessed the risk of bias of the included studies using the checklist recommended by the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD010968-bbs2-0017" title="HigginsJPT , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration 2011. Available from handbook.cochrane.org. ">Higgins 2011a</a>). We assessed the risk of bias according the following domains: sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective outcome reporting and other bias. Each domain was classified as 'low,' 'high' or 'unclear' risk of bias (<a href="./references#CD010968-bbs2-0018" title="HigginsJPT , AltmanDG , SterneJAC . Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011b</a>). For each entry, the judgement ('low risk' of bias, 'high risk' of bias, or 'unclear risk' of bias) was followed by a text box for a description of the design, conduct or observations that supported the judgement. There was no disagreement in assessing the risk of bias among the review authors. The final results were recorded in Review Manager 5 (<a href="./references#CD010968-bbs2-0033" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>). </p> </section> <section id="CD010968-sec-0051"> <h4 class="title">Measures of treatment effect</h4> <p>Data were managed according to the ITT principle. For each outcome, we calculated a summarised estimate of treatment effect (with 95% confidence interval (CI)) for each comparison. For dichotomous outcomes (e.g. relapses, disease progression), we used risk ratios (RR) and for continuous data (e.g. EDSS score), we used mean differences (MD). </p> </section> <section id="CD010968-sec-0052"> <h4 class="title">Unit of analysis issues</h4> <p>Cluster and cross‐over trials have not been carried out to evaluate alemtuzumab treatments for MS. We combined outcome data for participants who had relapses at 24 and 36 months and disability worsening at 24 and 36 months. When studies had multiple arms, we did not combine arms, and compared relevant arms separately in different analyses, to avoid double counting. </p> </section> <section id="CD010968-sec-0053"> <h4 class="title">Dealing with missing data</h4> <p>We contacted authors of identified studies to obtain additional information. If additional information was not obtained, we analysed the available data. </p> </section> <section id="CD010968-sec-0054"> <h4 class="title">Assessment of heterogeneity</h4> <p>We evaluated clinical and methodological heterogeneity across included studies by comparing characteristics of participants, interventions and study designs. </p> <p>We evaluated statistical heterogeneity among included studies using a Chi² test with an alpha of 0.1, and with the I² test. A P value of less than 0.1 and an I² statistic more than 50% was an indication of substantial statistical heterogeneity (<a href="./references#CD010968-bbs2-0017" title="HigginsJPT , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration 2011. Available from handbook.cochrane.org. ">Higgins 2011a</a>); we examined potential sources of clinical and methodological heterogeneity. </p> </section> <section id="CD010968-sec-0055"> <h4 class="title">Assessment of reporting biases</h4> <p>We did not use funnel plots to explore possible publication bias due to an insufficient number of included studies. </p> </section> <section id="CD010968-sec-0056"> <h4 class="title">Data synthesis</h4> <p>We used Review Manager 5 software to conduct formal meta‐analysis (<a href="./references#CD010968-bbs2-0033" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>). The selection of a fixed‐effect or random‐effects model was mainly based on the results of the Chi² test and I² statistic for heterogeneity (<a href="./references#CD010968-bbs2-0017" title="HigginsJPT , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration 2011. Available from handbook.cochrane.org. ">Higgins 2011a</a>). If the I² statistic indicated substantial statistical heterogeneity, we explored potential causes of heterogeneity first, to determine whether a subgroup analyses was needed. If the substantial heterogeneity still could not be explained, we adopted a random‐effects model. If the I² statistic indicated no significant statistical heterogeneity, we used a fixed‐effect model. </p> </section> <section id="CD010968-sec-0057"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We planned to perform the following subgroups analyses.</p> <p> <ul id="CD010968-list-0008"> <li> <p>Different dosages of alemtuzumab versus IFN beta 1a.</p> </li> <li> <p>Different duration of treatment.</p> </li> <li> <p>Different cointerventions.</p> </li> <li> <p>Different types of IFN beta 1a.</p> </li> </ul> </p> <p>However, because of the limited number of studies, we could not perform all the analyses.</p> </section> <section id="CD010968-sec-0058"> <h4 class="title">Sensitivity analysis</h4> <p>We planned to perform the following sensitivity analyses.</p> <p> <ul id="CD010968-list-0009"> <li> <p>Excluding studies at high risk of bias (i.e. non‐random sequence generation and inadequate allocation concealment, lack of blinded outcome assessor, lack of blinded participants/personnel, or a combination of these). </p> </li> <li> <p>Using a random‐effects model if a fixed‐effect model was used previously.</p> </li> </ul> </p> <p>However, because of the limited number of studies, we could not perform all the analyses.</p> <p><b>Summary of Findings</b> </p> <p>We presented the main results of the review in two 'Summary of findings' (SoF) tables, one reporting data for alemtuzumab 12 mg and one for alemtuzumab 24 mg, according to recommendations described in Chapter 11 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (version 5.1.0) (<a href="https://archie.cochrane.org/sections/documents/view?version=z1509160958313053524366638339633%26format=REVMAN#REF-Sch_x00fc_nemann-2011" target="_blank">Schünemann 2011</a>). We provided estimates from the pairwise meta‐analysis based on the methodology developed from the GRADE Working Group (<a href="https://archie.cochrane.org/sections/documents/view?version=z1509160958313053524366638339633%26format=REVMAN#REF-GRADE-Working-Group-2004" target="_blank">GRADE Working Group 2004</a>). We included an overall grading of the evidence for seven patient‐important outcomes: </p> <p> <ul id="CD010968-list-0010"> <li> <p>Number of participants experiencing at least one relapse</p> </li> <li> <p>Number of participants whose disability worsened</p> </li> <li> <p>Number of participants with at least one adverse events</p> </li> <li> <p>Number of participants with serious adverse events</p> </li> <li> <p>Mean Expanded Disability Status Scale score change from baseline</p> </li> <li> <p>Number of participants with new T2‐hyperintense lesions on magnetic resonance imaging</p> </li> <li> <p>Number of participants experiencing treatment discontinuation caused by adverse events</p> </li> </ul> </p> <p>We graded the quality of evidence for each outcome considering study limitations, indirectness, inconsistency, imprecision of effect estimates, and risk of reporting bias, assigning four levels of quality of evidence: high, moderate, low, and very low. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD010968-sec-0059" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD010968-sec-0059"></div> <section id="CD010968-sec-0060"> <h3 class="title">Description of studies</h3> <section id="CD010968-sec-0061"> <h4 class="title">Results of the search</h4> <p>The search strategies retrieved 316 references. After screening of titles and abstracts, we obtained 19 full papers (three studies) and assessed them for eligibility (<a href="#CD010968-fig-0001">Figure 1</a>). </p> <div class="figure" id="CD010968-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD010968-fig-0001" src="/cdsr/doi/10.1002/14651858.CD010968.pub2/media/CDSR/CD010968/image_n/nCD010968-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD010968-sec-0062"> <h4 class="title">Included studies</h4> <p>We included three studies involving 1694 participants in the review. All three studies were multicentric RCTs comparing alemtuzumab versus IFN beta 1a in the treatment of people with RRMS. <a href="./references#CD010968-bbs2-0001" title="ButtonT , AltmannD , TozerD , DaltonC , CompstonD , MillerD , et al. Magnetisation transfer imaging of alemtuzumab treatment of multiple sclerosis. Multiple Sclerosis2013;19(2):241‐4. CAMMS223 Trial Investigators, ColesAJ , CompstonDA , SelmajKW , LakeSL , MoranS , MargolinDH , et al. Alemtuzumab vs. interferon beta‐1a in early multiple sclerosis. New England Journal of Medicine2008;359(17):1786‐801. ColesAJ , FoxE , VladicA , GazdaSK , BrinarV , SelmajKW , et al. Alemtuzumab more effective than interferon β‐1a at 5‐year follow‐up of CAMMS223 clinical trial. Neurology2012;78(14):1069‐78. ColesAJ , FoxE , VladicA , GazdaSK , BrinarV , SelmajKW , et al. Alemtuzumab versus interferon β‐1a in early relapsing‐remitting multiple sclerosis: post‐hoc and subset analyses of clinical efficacy outcomes. Lancet Neurology2011;10(4):338‐48. DanielsG , VladicA , BrinarV , ZavalishinI , ValenteW , OyuelaP , et al. Alemtuzumab‐related thyroid dysfunction in a phase 2 trial of patients with relapsing‐remitting multiple sclerosis. Journal of Clinical Endocrinology and Metabolism2014;99(1):80‐9. GravesJ , GalettaS , PalmerJ , MargolinD , RizzoM , BilbruckJ , et al. Alemtuzumab improves contrast sensitivity in patients with relapsing‐remitting multiple sclerosis. Multiple Sclerosis2013;19(10):1302‐9. ">CAMMS223 2008</a> and <a href="./references#CD010968-bbs2-0003" title="ColesAJ , TwymanCL , ArnoldDL , CohenJA , ConfavreuxC , FoxEJ , et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease‐modifying therapy: a randomised controlled phase 3 trial. Lancet2012;380(9856):1829‐39. FernandezO , ArnoldD , CohenJ , ColesA , ConfavreuxC , FoxE , et al. Alemtuzumab improves disability by month 6 independent of relapse history in relapsing‐remitting multiple sclerosis patients: CARE‐MS II. Journal of Neurology2013;260:Suppl 14. FoxE , ArnoldD , CohenJ , ColesA , ConfavreuxC , HartungH , et al. Durable efficacy of alemtuzumab in relapsing‐remitting multiple sclerosis patients who participated in the CARE‐MS studies: three year follow‐up. Neurology2013;80:Suppl 7. GiovannoniG , ArnoldD , CohenJ , ColesA , ConfavreuxC , FoxE , et al. Disability improvement with alemtuzumab vs. interferon beta‐1a in relapsing‐remitting multiple sclerosis patients who experienced disease activity while on prior therapy (CARE‐MS II). Neurology2013;80:Suppl 7. HartungH , ArnoldD , CohenJ , ColesA , ConfavreuxC , FoxE , et al. Disability outcomes for alemtuzumab in RRMS patients who relapsed on prior therapy: CARE‐MS II. Journal of Neurology2012;259(1):Suppl 47‐8. HartungH , VollmerT , ArnoldD , CohenJ , ColesA , ConfavreuxC , et al. Alemtuzumab reduces ms disease activity in active relapsing‐remitting multiple sclerosis patients who had disease activity on prior therapy. Neurology2013;80:Suppl 7. ">CARE‐MS II</a> are three‐arm trials. We did not merge multi‐arm trials involving alemtuzumab at different doses compared to Interferon Beta treatment and presented separate data for each arm. </p> <p><a href="./references#CD010968-bbs2-0001" title="ButtonT , AltmannD , TozerD , DaltonC , CompstonD , MillerD , et al. Magnetisation transfer imaging of alemtuzumab treatment of multiple sclerosis. Multiple Sclerosis2013;19(2):241‐4. CAMMS223 Trial Investigators, ColesAJ , CompstonDA , SelmajKW , LakeSL , MoranS , MargolinDH , et al. Alemtuzumab vs. interferon beta‐1a in early multiple sclerosis. New England Journal of Medicine2008;359(17):1786‐801. ColesAJ , FoxE , VladicA , GazdaSK , BrinarV , SelmajKW , et al. Alemtuzumab more effective than interferon β‐1a at 5‐year follow‐up of CAMMS223 clinical trial. Neurology2012;78(14):1069‐78. ColesAJ , FoxE , VladicA , GazdaSK , BrinarV , SelmajKW , et al. Alemtuzumab versus interferon β‐1a in early relapsing‐remitting multiple sclerosis: post‐hoc and subset analyses of clinical efficacy outcomes. Lancet Neurology2011;10(4):338‐48. DanielsG , VladicA , BrinarV , ZavalishinI , ValenteW , OyuelaP , et al. Alemtuzumab‐related thyroid dysfunction in a phase 2 trial of patients with relapsing‐remitting multiple sclerosis. Journal of Clinical Endocrinology and Metabolism2014;99(1):80‐9. GravesJ , GalettaS , PalmerJ , MargolinD , RizzoM , BilbruckJ , et al. Alemtuzumab improves contrast sensitivity in patients with relapsing‐remitting multiple sclerosis. Multiple Sclerosis2013;19(10):1302‐9. ">CAMMS223 2008</a> involved participants with previously untreated, early RRMS. Participants received either subcutaneous IFN beta 1a 44 μg three times per week or annual intravenous cycles of alemtuzumab at either 12 mg per day or 24 mg per day. </p> <p><a href="./references#CD010968-bbs2-0002" title="ArnoldD , BrinarV , CohenJ , ColesA , ConfavreuxC , FisherE , et al. Effect of alemtuzumab vs. Rebif (registered trademark) on brain MRI measurements: results of CARE‐MS I, a phase 3 study. Neurology2012; Vol. 78, issue 1:S11.006. BalcerL , ArnoldD , CohenJ , ColesA , ConfavreuxC , FoxE , et al. Alemtuzumab improves visual outcomes in treatment‐naive patients with relapsing‐remitting multiple sclerosis (RRMS): analysis from the phase 3 CARE‐MS I study. Journal of the Neurological Sciences2013;333:e375. CohenJA , ColesAJ , ArnoldDL , ConfavreuxC , FoxEJ , HartungHP , et al. Alemtuzumab versus interferon beta 1a as first‐line treatment for patients with relapsing‐remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet2012;380(9856):1819‐28. ColesA , BrinarV , ArnoldD , CohenJ , ConfavreauxC , FoxE , et al. Efficacy and safety results from CARE‐MS I: a phase 3 study comparing alemtuzumab and interferon‐(beta)‐1a. Multiple Sclerosis2011;17(10):Suppl 510. FoxE , ArnoldD , BrinarV , CohenJ , ColesA , ConfavreuxC , et al. Relapse outcomes with alemtuzumab vs. Rebif (registered trademark) in treatment‐naive relapsing‐remitting multiple sclerosis (CARE‐MS I): secondary and tertiary endpoints. Neurology2012;78(1):Suppl PD5.004. FoxE , ArnoldD , CohenJ , ColesA , ConfavreuxC , HartungH , et al. Durable efficacy of alemtuzumab in relapsing‐remitting multiple sclerosis patients who participated in the CARE‐MS studies: three year follow‐up. Neurology2013;80(7):Suppl 41.001. GiovannoniG , ArnoldD , CohenJ , ColesA , ConfavreuxC , FoxH , et al. Disease activity‐free status in comparison of alemtuzumab and Rebif (registered trademark) efficacy in multiple sclerosis I (CARE‐MS I) phase 3 study. Journal of Neurology2012;259(1):Suppl 47. ">CARE‐MS I</a> enrolled adults aged 18 to 50 years with previously untreated RRMS. Participants received annual intravenous cycles of alemtuzumab 12 mg per day or subcutaneous IFN beta 1a 44 μg three times per week. </p> <p><a href="./references#CD010968-bbs2-0003" title="ColesAJ , TwymanCL , ArnoldDL , CohenJA , ConfavreuxC , FoxEJ , et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease‐modifying therapy: a randomised controlled phase 3 trial. Lancet2012;380(9856):1829‐39. FernandezO , ArnoldD , CohenJ , ColesA , ConfavreuxC , FoxE , et al. Alemtuzumab improves disability by month 6 independent of relapse history in relapsing‐remitting multiple sclerosis patients: CARE‐MS II. Journal of Neurology2013;260:Suppl 14. FoxE , ArnoldD , CohenJ , ColesA , ConfavreuxC , HartungH , et al. Durable efficacy of alemtuzumab in relapsing‐remitting multiple sclerosis patients who participated in the CARE‐MS studies: three year follow‐up. Neurology2013;80:Suppl 7. GiovannoniG , ArnoldD , CohenJ , ColesA , ConfavreuxC , FoxE , et al. Disability improvement with alemtuzumab vs. interferon beta‐1a in relapsing‐remitting multiple sclerosis patients who experienced disease activity while on prior therapy (CARE‐MS II). Neurology2013;80:Suppl 7. HartungH , ArnoldD , CohenJ , ColesA , ConfavreuxC , FoxE , et al. Disability outcomes for alemtuzumab in RRMS patients who relapsed on prior therapy: CARE‐MS II. Journal of Neurology2012;259(1):Suppl 47‐8. HartungH , VollmerT , ArnoldD , CohenJ , ColesA , ConfavreuxC , et al. Alemtuzumab reduces ms disease activity in active relapsing‐remitting multiple sclerosis patients who had disease activity on prior therapy. Neurology2013;80:Suppl 7. ">CARE‐MS II</a> enrolled adults aged 18 to 55 years with RRMS and at least one relapse on IFN beta or glatiramer. Participants received subcutaneous IFN beta 1a 44 μg three times per week, annual intravenous cycles of alemtuzumab 12 mg per day or annual intravenous cycles of alemtuzumab 24 mg per day. The 24 mg per day group was discontinued to aid recruitment, data were included for safety assessments, but data for benetif outcomes were not provided. </p> </section> <section id="CD010968-sec-0063"> <h4 class="title">Excluded studies</h4> <p>We excluded none of the potentially eligible studies.</p> </section> </section> <section id="CD010968-sec-0064"> <h3 class="title">Risk of bias in included studies</h3> <p>The risk of bias summaries are provided in <a href="#CD010968-fig-0002">Figure 2</a> and <a href="#CD010968-fig-0003">Figure 3</a>. </p> <div class="figure" id="CD010968-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD010968-fig-0002" src="/cdsr/doi/10.1002/14651858.CD010968.pub2/media/CDSR/CD010968/image_n/nCD010968-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD010968-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD010968-fig-0003" src="/cdsr/doi/10.1002/14651858.CD010968.pub2/media/CDSR/CD010968/image_n/nCD010968-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD010968-sec-0065"> <h4 class="title">Allocation</h4> <p>All three included trials were reported as randomised; <a href="./references#CD010968-bbs2-0001" title="ButtonT , AltmannD , TozerD , DaltonC , CompstonD , MillerD , et al. Magnetisation transfer imaging of alemtuzumab treatment of multiple sclerosis. Multiple Sclerosis2013;19(2):241‐4. CAMMS223 Trial Investigators, ColesAJ , CompstonDA , SelmajKW , LakeSL , MoranS , MargolinDH , et al. Alemtuzumab vs. interferon beta‐1a in early multiple sclerosis. New England Journal of Medicine2008;359(17):1786‐801. ColesAJ , FoxE , VladicA , GazdaSK , BrinarV , SelmajKW , et al. Alemtuzumab more effective than interferon β‐1a at 5‐year follow‐up of CAMMS223 clinical trial. Neurology2012;78(14):1069‐78. ColesAJ , FoxE , VladicA , GazdaSK , BrinarV , SelmajKW , et al. Alemtuzumab versus interferon β‐1a in early relapsing‐remitting multiple sclerosis: post‐hoc and subset analyses of clinical efficacy outcomes. Lancet Neurology2011;10(4):338‐48. DanielsG , VladicA , BrinarV , ZavalishinI , ValenteW , OyuelaP , et al. Alemtuzumab‐related thyroid dysfunction in a phase 2 trial of patients with relapsing‐remitting multiple sclerosis. Journal of Clinical Endocrinology and Metabolism2014;99(1):80‐9. GravesJ , GalettaS , PalmerJ , MargolinD , RizzoM , BilbruckJ , et al. Alemtuzumab improves contrast sensitivity in patients with relapsing‐remitting multiple sclerosis. Multiple Sclerosis2013;19(10):1302‐9. ">CAMMS223 2008</a> used the Pocock and Simon minimisation algorithm, while <a href="./references#CD010968-bbs2-0002" title="ArnoldD , BrinarV , CohenJ , ColesA , ConfavreuxC , FisherE , et al. Effect of alemtuzumab vs. Rebif (registered trademark) on brain MRI measurements: results of CARE‐MS I, a phase 3 study. Neurology2012; Vol. 78, issue 1:S11.006. BalcerL , ArnoldD , CohenJ , ColesA , ConfavreuxC , FoxE , et al. Alemtuzumab improves visual outcomes in treatment‐naive patients with relapsing‐remitting multiple sclerosis (RRMS): analysis from the phase 3 CARE‐MS I study. Journal of the Neurological Sciences2013;333:e375. CohenJA , ColesAJ , ArnoldDL , ConfavreuxC , FoxEJ , HartungHP , et al. Alemtuzumab versus interferon beta 1a as first‐line treatment for patients with relapsing‐remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet2012;380(9856):1819‐28. ColesA , BrinarV , ArnoldD , CohenJ , ConfavreauxC , FoxE , et al. Efficacy and safety results from CARE‐MS I: a phase 3 study comparing alemtuzumab and interferon‐(beta)‐1a. Multiple Sclerosis2011;17(10):Suppl 510. FoxE , ArnoldD , BrinarV , CohenJ , ColesA , ConfavreuxC , et al. Relapse outcomes with alemtuzumab vs. Rebif (registered trademark) in treatment‐naive relapsing‐remitting multiple sclerosis (CARE‐MS I): secondary and tertiary endpoints. Neurology2012;78(1):Suppl PD5.004. FoxE , ArnoldD , CohenJ , ColesA , ConfavreuxC , HartungH , et al. Durable efficacy of alemtuzumab in relapsing‐remitting multiple sclerosis patients who participated in the CARE‐MS studies: three year follow‐up. Neurology2013;80(7):Suppl 41.001. GiovannoniG , ArnoldD , CohenJ , ColesA , ConfavreuxC , FoxH , et al. Disease activity‐free status in comparison of alemtuzumab and Rebif (registered trademark) efficacy in multiple sclerosis I (CARE‐MS I) phase 3 study. Journal of Neurology2012;259(1):Suppl 47. ">CARE‐MS I</a> and <a href="./references#CD010968-bbs2-0003" title="ColesAJ , TwymanCL , ArnoldDL , CohenJA , ConfavreuxC , FoxEJ , et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease‐modifying therapy: a randomised controlled phase 3 trial. Lancet2012;380(9856):1829‐39. FernandezO , ArnoldD , CohenJ , ColesA , ConfavreuxC , FoxE , et al. Alemtuzumab improves disability by month 6 independent of relapse history in relapsing‐remitting multiple sclerosis patients: CARE‐MS II. Journal of Neurology2013;260:Suppl 14. FoxE , ArnoldD , CohenJ , ColesA , ConfavreuxC , HartungH , et al. Durable efficacy of alemtuzumab in relapsing‐remitting multiple sclerosis patients who participated in the CARE‐MS studies: three year follow‐up. Neurology2013;80:Suppl 7. GiovannoniG , ArnoldD , CohenJ , ColesA , ConfavreuxC , FoxE , et al. Disability improvement with alemtuzumab vs. interferon beta‐1a in relapsing‐remitting multiple sclerosis patients who experienced disease activity while on prior therapy (CARE‐MS II). Neurology2013;80:Suppl 7. HartungH , ArnoldD , CohenJ , ColesA , ConfavreuxC , FoxE , et al. Disability outcomes for alemtuzumab in RRMS patients who relapsed on prior therapy: CARE‐MS II. Journal of Neurology2012;259(1):Suppl 47‐8. HartungH , VollmerT , ArnoldD , CohenJ , ColesA , ConfavreuxC , et al. Alemtuzumab reduces ms disease activity in active relapsing‐remitting multiple sclerosis patients who had disease activity on prior therapy. Neurology2013;80:Suppl 7. ">CARE‐MS II</a> used an interactive voice response system. Thus, the three studies were at low risk of bias for random sequence generation. </p> <p>For allocation concealment, <a href="./references#CD010968-bbs2-0002" title="ArnoldD , BrinarV , CohenJ , ColesA , ConfavreuxC , FisherE , et al. Effect of alemtuzumab vs. Rebif (registered trademark) on brain MRI measurements: results of CARE‐MS I, a phase 3 study. Neurology2012; Vol. 78, issue 1:S11.006. BalcerL , ArnoldD , CohenJ , ColesA , ConfavreuxC , FoxE , et al. Alemtuzumab improves visual outcomes in treatment‐naive patients with relapsing‐remitting multiple sclerosis (RRMS): analysis from the phase 3 CARE‐MS I study. Journal of the Neurological Sciences2013;333:e375. CohenJA , ColesAJ , ArnoldDL , ConfavreuxC , FoxEJ , HartungHP , et al. Alemtuzumab versus interferon beta 1a as first‐line treatment for patients with relapsing‐remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet2012;380(9856):1819‐28. ColesA , BrinarV , ArnoldD , CohenJ , ConfavreauxC , FoxE , et al. Efficacy and safety results from CARE‐MS I: a phase 3 study comparing alemtuzumab and interferon‐(beta)‐1a. Multiple Sclerosis2011;17(10):Suppl 510. FoxE , ArnoldD , BrinarV , CohenJ , ColesA , ConfavreuxC , et al. Relapse outcomes with alemtuzumab vs. Rebif (registered trademark) in treatment‐naive relapsing‐remitting multiple sclerosis (CARE‐MS I): secondary and tertiary endpoints. Neurology2012;78(1):Suppl PD5.004. FoxE , ArnoldD , CohenJ , ColesA , ConfavreuxC , HartungH , et al. Durable efficacy of alemtuzumab in relapsing‐remitting multiple sclerosis patients who participated in the CARE‐MS studies: three year follow‐up. Neurology2013;80(7):Suppl 41.001. GiovannoniG , ArnoldD , CohenJ , ColesA , ConfavreuxC , FoxH , et al. Disease activity‐free status in comparison of alemtuzumab and Rebif (registered trademark) efficacy in multiple sclerosis I (CARE‐MS I) phase 3 study. Journal of Neurology2012;259(1):Suppl 47. ">CARE‐MS I</a> and <a href="./references#CD010968-bbs2-0003" title="ColesAJ , TwymanCL , ArnoldDL , CohenJA , ConfavreuxC , FoxEJ , et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease‐modifying therapy: a randomised controlled phase 3 trial. Lancet2012;380(9856):1829‐39. FernandezO , ArnoldD , CohenJ , ColesA , ConfavreuxC , FoxE , et al. Alemtuzumab improves disability by month 6 independent of relapse history in relapsing‐remitting multiple sclerosis patients: CARE‐MS II. Journal of Neurology2013;260:Suppl 14. FoxE , ArnoldD , CohenJ , ColesA , ConfavreuxC , HartungH , et al. Durable efficacy of alemtuzumab in relapsing‐remitting multiple sclerosis patients who participated in the CARE‐MS studies: three year follow‐up. Neurology2013;80:Suppl 7. GiovannoniG , ArnoldD , CohenJ , ColesA , ConfavreuxC , FoxE , et al. Disability improvement with alemtuzumab vs. interferon beta‐1a in relapsing‐remitting multiple sclerosis patients who experienced disease activity while on prior therapy (CARE‐MS II). Neurology2013;80:Suppl 7. HartungH , ArnoldD , CohenJ , ColesA , ConfavreuxC , FoxE , et al. Disability outcomes for alemtuzumab in RRMS patients who relapsed on prior therapy: CARE‐MS II. Journal of Neurology2012;259(1):Suppl 47‐8. HartungH , VollmerT , ArnoldD , CohenJ , ColesA , ConfavreuxC , et al. Alemtuzumab reduces ms disease activity in active relapsing‐remitting multiple sclerosis patients who had disease activity on prior therapy. Neurology2013;80:Suppl 7. ">CARE‐MS II</a> used an interactive voice response system, thus we assessed them at low risk of bias. <a href="./references#CD010968-bbs2-0001" title="ButtonT , AltmannD , TozerD , DaltonC , CompstonD , MillerD , et al. Magnetisation transfer imaging of alemtuzumab treatment of multiple sclerosis. Multiple Sclerosis2013;19(2):241‐4. CAMMS223 Trial Investigators, ColesAJ , CompstonDA , SelmajKW , LakeSL , MoranS , MargolinDH , et al. Alemtuzumab vs. interferon beta‐1a in early multiple sclerosis. New England Journal of Medicine2008;359(17):1786‐801. ColesAJ , FoxE , VladicA , GazdaSK , BrinarV , SelmajKW , et al. Alemtuzumab more effective than interferon β‐1a at 5‐year follow‐up of CAMMS223 clinical trial. Neurology2012;78(14):1069‐78. ColesAJ , FoxE , VladicA , GazdaSK , BrinarV , SelmajKW , et al. Alemtuzumab versus interferon β‐1a in early relapsing‐remitting multiple sclerosis: post‐hoc and subset analyses of clinical efficacy outcomes. Lancet Neurology2011;10(4):338‐48. DanielsG , VladicA , BrinarV , ZavalishinI , ValenteW , OyuelaP , et al. Alemtuzumab‐related thyroid dysfunction in a phase 2 trial of patients with relapsing‐remitting multiple sclerosis. Journal of Clinical Endocrinology and Metabolism2014;99(1):80‐9. GravesJ , GalettaS , PalmerJ , MargolinD , RizzoM , BilbruckJ , et al. Alemtuzumab improves contrast sensitivity in patients with relapsing‐remitting multiple sclerosis. Multiple Sclerosis2013;19(10):1302‐9. ">CAMMS223 2008</a> did not mention allocation concealment, thus, we assessed it at unclear risk of bias. </p> </section> <section id="CD010968-sec-0066"> <h4 class="title">Blinding</h4> <p>We considered all studies at high risk of bias of performance bias (participants and personnel) because both drugs (intervention and comparator) had adverse effects that precluded masking. </p> </section> <section id="CD010968-sec-0067"> <h4 class="title">Incomplete outcome data</h4> <p>All three trials provided sufficient details about the number of, and the reasons for, dropout. In <a href="./references#CD010968-bbs2-0001" title="ButtonT , AltmannD , TozerD , DaltonC , CompstonD , MillerD , et al. Magnetisation transfer imaging of alemtuzumab treatment of multiple sclerosis. Multiple Sclerosis2013;19(2):241‐4. CAMMS223 Trial Investigators, ColesAJ , CompstonDA , SelmajKW , LakeSL , MoranS , MargolinDH , et al. Alemtuzumab vs. interferon beta‐1a in early multiple sclerosis. New England Journal of Medicine2008;359(17):1786‐801. ColesAJ , FoxE , VladicA , GazdaSK , BrinarV , SelmajKW , et al. Alemtuzumab more effective than interferon β‐1a at 5‐year follow‐up of CAMMS223 clinical trial. Neurology2012;78(14):1069‐78. ColesAJ , FoxE , VladicA , GazdaSK , BrinarV , SelmajKW , et al. Alemtuzumab versus interferon β‐1a in early relapsing‐remitting multiple sclerosis: post‐hoc and subset analyses of clinical efficacy outcomes. Lancet Neurology2011;10(4):338‐48. DanielsG , VladicA , BrinarV , ZavalishinI , ValenteW , OyuelaP , et al. Alemtuzumab‐related thyroid dysfunction in a phase 2 trial of patients with relapsing‐remitting multiple sclerosis. Journal of Clinical Endocrinology and Metabolism2014;99(1):80‐9. GravesJ , GalettaS , PalmerJ , MargolinD , RizzoM , BilbruckJ , et al. Alemtuzumab improves contrast sensitivity in patients with relapsing‐remitting multiple sclerosis. Multiple Sclerosis2013;19(10):1302‐9. ">CAMMS223 2008</a>, the dropout rate was unbalanced between the alemtuzumab group (17%) and the IFN beta 1a group (41%), therefore, we classified the trial at high risk. In <a href="./references#CD010968-bbs2-0002" title="ArnoldD , BrinarV , CohenJ , ColesA , ConfavreuxC , FisherE , et al. Effect of alemtuzumab vs. Rebif (registered trademark) on brain MRI measurements: results of CARE‐MS I, a phase 3 study. Neurology2012; Vol. 78, issue 1:S11.006. BalcerL , ArnoldD , CohenJ , ColesA , ConfavreuxC , FoxE , et al. Alemtuzumab improves visual outcomes in treatment‐naive patients with relapsing‐remitting multiple sclerosis (RRMS): analysis from the phase 3 CARE‐MS I study. Journal of the Neurological Sciences2013;333:e375. CohenJA , ColesAJ , ArnoldDL , ConfavreuxC , FoxEJ , HartungHP , et al. Alemtuzumab versus interferon beta 1a as first‐line treatment for patients with relapsing‐remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet2012;380(9856):1819‐28. ColesA , BrinarV , ArnoldD , CohenJ , ConfavreauxC , FoxE , et al. Efficacy and safety results from CARE‐MS I: a phase 3 study comparing alemtuzumab and interferon‐(beta)‐1a. Multiple Sclerosis2011;17(10):Suppl 510. FoxE , ArnoldD , BrinarV , CohenJ , ColesA , ConfavreuxC , et al. Relapse outcomes with alemtuzumab vs. Rebif (registered trademark) in treatment‐naive relapsing‐remitting multiple sclerosis (CARE‐MS I): secondary and tertiary endpoints. Neurology2012;78(1):Suppl PD5.004. FoxE , ArnoldD , CohenJ , ColesA , ConfavreuxC , HartungH , et al. Durable efficacy of alemtuzumab in relapsing‐remitting multiple sclerosis patients who participated in the CARE‐MS studies: three year follow‐up. Neurology2013;80(7):Suppl 41.001. GiovannoniG , ArnoldD , CohenJ , ColesA , ConfavreuxC , FoxH , et al. Disease activity‐free status in comparison of alemtuzumab and Rebif (registered trademark) efficacy in multiple sclerosis I (CARE‐MS I) phase 3 study. Journal of Neurology2012;259(1):Suppl 47. ">CARE‐MS I</a>, the percentage of dropout was unbalanced between alemtuzumab group (6%) and IFN beta 1a group (16%), therefore, we classified the trial at high risk of incomplete outcome data bias. In <a href="./references#CD010968-bbs2-0003" title="ColesAJ , TwymanCL , ArnoldDL , CohenJA , ConfavreuxC , FoxEJ , et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease‐modifying therapy: a randomised controlled phase 3 trial. Lancet2012;380(9856):1829‐39. FernandezO , ArnoldD , CohenJ , ColesA , ConfavreuxC , FoxE , et al. Alemtuzumab improves disability by month 6 independent of relapse history in relapsing‐remitting multiple sclerosis patients: CARE‐MS II. Journal of Neurology2013;260:Suppl 14. FoxE , ArnoldD , CohenJ , ColesA , ConfavreuxC , HartungH , et al. Durable efficacy of alemtuzumab in relapsing‐remitting multiple sclerosis patients who participated in the CARE‐MS studies: three year follow‐up. Neurology2013;80:Suppl 7. GiovannoniG , ArnoldD , CohenJ , ColesA , ConfavreuxC , FoxE , et al. Disability improvement with alemtuzumab vs. interferon beta‐1a in relapsing‐remitting multiple sclerosis patients who experienced disease activity while on prior therapy (CARE‐MS II). Neurology2013;80:Suppl 7. HartungH , ArnoldD , CohenJ , ColesA , ConfavreuxC , FoxE , et al. Disability outcomes for alemtuzumab in RRMS patients who relapsed on prior therapy: CARE‐MS II. Journal of Neurology2012;259(1):Suppl 47‐8. HartungH , VollmerT , ArnoldD , CohenJ , ColesA , ConfavreuxC , et al. Alemtuzumab reduces ms disease activity in active relapsing‐remitting multiple sclerosis patients who had disease activity on prior therapy. Neurology2013;80:Suppl 7. ">CARE‐MS II</a>, the percentage of dropout was unbalanced between alemtuzumab group (2.1%) and IFN beta 1a group (12.6%), therefore, we classified the trial at high risk of incomplete outcome data bias. </p> </section> <section id="CD010968-sec-0068"> <h4 class="title">Selective reporting</h4> <p>All three trials were at low risk of reporting bias as they reported all specified primary and secondary outcomes. </p> </section> <section id="CD010968-sec-0069"> <h4 class="title">Other potential sources of bias</h4> <p>We did not find any other potential souce of bias.</p> </section> </section> <section id="CD010968-sec-0070"> <h3 class="title" id="CD010968-sec-0070">Effects of interventions</h3> <p>See: <a href="./full#CD010968-tbl-0001"><b>Summary of findings for the main comparison</b> Alemtuzumab 12 mg compared to interferon beta 1a for relapsing‐remitting multiple sclerosis</a>; <a href="./full#CD010968-tbl-0002"><b>Summary of findings 2</b> Alemtuzumab 24 mg compared to interferon beta 1a for relapsing‐remitting multiple sclerosis</a> </p> <section id="CD010968-sec-0071"> <h4 class="title">Primary outcomes</h4> <section id="CD010968-sec-0072"> <h5 class="title">Number of participants experiencing at least one relapse at 24 and 36 months</h5> <p>All three trials assessed the number of participants experiencing at least one relapse at 24 and 36 months (<a href="./references#CD010968-bbs2-0001" title="ButtonT , AltmannD , TozerD , DaltonC , CompstonD , MillerD , et al. Magnetisation transfer imaging of alemtuzumab treatment of multiple sclerosis. Multiple Sclerosis2013;19(2):241‐4. CAMMS223 Trial Investigators, ColesAJ , CompstonDA , SelmajKW , LakeSL , MoranS , MargolinDH , et al. Alemtuzumab vs. interferon beta‐1a in early multiple sclerosis. New England Journal of Medicine2008;359(17):1786‐801. ColesAJ , FoxE , VladicA , GazdaSK , BrinarV , SelmajKW , et al. Alemtuzumab more effective than interferon β‐1a at 5‐year follow‐up of CAMMS223 clinical trial. Neurology2012;78(14):1069‐78. ColesAJ , FoxE , VladicA , GazdaSK , BrinarV , SelmajKW , et al. Alemtuzumab versus interferon β‐1a in early relapsing‐remitting multiple sclerosis: post‐hoc and subset analyses of clinical efficacy outcomes. Lancet Neurology2011;10(4):338‐48. DanielsG , VladicA , BrinarV , ZavalishinI , ValenteW , OyuelaP , et al. Alemtuzumab‐related thyroid dysfunction in a phase 2 trial of patients with relapsing‐remitting multiple sclerosis. Journal of Clinical Endocrinology and Metabolism2014;99(1):80‐9. GravesJ , GalettaS , PalmerJ , MargolinD , RizzoM , BilbruckJ , et al. Alemtuzumab improves contrast sensitivity in patients with relapsing‐remitting multiple sclerosis. Multiple Sclerosis2013;19(10):1302‐9. ">CAMMS223 2008</a>; <a href="./references#CD010968-bbs2-0002" title="ArnoldD , BrinarV , CohenJ , ColesA , ConfavreuxC , FisherE , et al. Effect of alemtuzumab vs. Rebif (registered trademark) on brain MRI measurements: results of CARE‐MS I, a phase 3 study. Neurology2012; Vol. 78, issue 1:S11.006. BalcerL , ArnoldD , CohenJ , ColesA , ConfavreuxC , FoxE , et al. Alemtuzumab improves visual outcomes in treatment‐naive patients with relapsing‐remitting multiple sclerosis (RRMS): analysis from the phase 3 CARE‐MS I study. Journal of the Neurological Sciences2013;333:e375. CohenJA , ColesAJ , ArnoldDL , ConfavreuxC , FoxEJ , HartungHP , et al. Alemtuzumab versus interferon beta 1a as first‐line treatment for patients with relapsing‐remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet2012;380(9856):1819‐28. ColesA , BrinarV , ArnoldD , CohenJ , ConfavreauxC , FoxE , et al. Efficacy and safety results from CARE‐MS I: a phase 3 study comparing alemtuzumab and interferon‐(beta)‐1a. Multiple Sclerosis2011;17(10):Suppl 510. FoxE , ArnoldD , BrinarV , CohenJ , ColesA , ConfavreuxC , et al. Relapse outcomes with alemtuzumab vs. Rebif (registered trademark) in treatment‐naive relapsing‐remitting multiple sclerosis (CARE‐MS I): secondary and tertiary endpoints. Neurology2012;78(1):Suppl PD5.004. FoxE , ArnoldD , CohenJ , ColesA , ConfavreuxC , HartungH , et al. Durable efficacy of alemtuzumab in relapsing‐remitting multiple sclerosis patients who participated in the CARE‐MS studies: three year follow‐up. Neurology2013;80(7):Suppl 41.001. GiovannoniG , ArnoldD , CohenJ , ColesA , ConfavreuxC , FoxH , et al. Disease activity‐free status in comparison of alemtuzumab and Rebif (registered trademark) efficacy in multiple sclerosis I (CARE‐MS I) phase 3 study. Journal of Neurology2012;259(1):Suppl 47. ">CARE‐MS I</a>; <a href="./references#CD010968-bbs2-0003" title="ColesAJ , TwymanCL , ArnoldDL , CohenJA , ConfavreuxC , FoxEJ , et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease‐modifying therapy: a randomised controlled phase 3 trial. Lancet2012;380(9856):1829‐39. FernandezO , ArnoldD , CohenJ , ColesA , ConfavreuxC , FoxE , et al. Alemtuzumab improves disability by month 6 independent of relapse history in relapsing‐remitting multiple sclerosis patients: CARE‐MS II. Journal of Neurology2013;260:Suppl 14. FoxE , ArnoldD , CohenJ , ColesA , ConfavreuxC , HartungH , et al. Durable efficacy of alemtuzumab in relapsing‐remitting multiple sclerosis patients who participated in the CARE‐MS studies: three year follow‐up. Neurology2013;80:Suppl 7. GiovannoniG , ArnoldD , CohenJ , ColesA , ConfavreuxC , FoxE , et al. Disability improvement with alemtuzumab vs. interferon beta‐1a in relapsing‐remitting multiple sclerosis patients who experienced disease activity while on prior therapy (CARE‐MS II). Neurology2013;80:Suppl 7. HartungH , ArnoldD , CohenJ , ColesA , ConfavreuxC , FoxE , et al. Disability outcomes for alemtuzumab in RRMS patients who relapsed on prior therapy: CARE‐MS II. Journal of Neurology2012;259(1):Suppl 47‐8. HartungH , VollmerT , ArnoldD , CohenJ , ColesA , ConfavreuxC , et al. Alemtuzumab reduces ms disease activity in active relapsing‐remitting multiple sclerosis patients who had disease activity on prior therapy. Neurology2013;80:Suppl 7. ">CARE‐MS II</a>). <a href="./references#CD010968-bbs2-0001" title="ButtonT , AltmannD , TozerD , DaltonC , CompstonD , MillerD , et al. Magnetisation transfer imaging of alemtuzumab treatment of multiple sclerosis. Multiple Sclerosis2013;19(2):241‐4. CAMMS223 Trial Investigators, ColesAJ , CompstonDA , SelmajKW , LakeSL , MoranS , MargolinDH , et al. Alemtuzumab vs. interferon beta‐1a in early multiple sclerosis. New England Journal of Medicine2008;359(17):1786‐801. ColesAJ , FoxE , VladicA , GazdaSK , BrinarV , SelmajKW , et al. Alemtuzumab more effective than interferon β‐1a at 5‐year follow‐up of CAMMS223 clinical trial. Neurology2012;78(14):1069‐78. ColesAJ , FoxE , VladicA , GazdaSK , BrinarV , SelmajKW , et al. Alemtuzumab versus interferon β‐1a in early relapsing‐remitting multiple sclerosis: post‐hoc and subset analyses of clinical efficacy outcomes. Lancet Neurology2011;10(4):338‐48. DanielsG , VladicA , BrinarV , ZavalishinI , ValenteW , OyuelaP , et al. Alemtuzumab‐related thyroid dysfunction in a phase 2 trial of patients with relapsing‐remitting multiple sclerosis. Journal of Clinical Endocrinology and Metabolism2014;99(1):80‐9. GravesJ , GalettaS , PalmerJ , MargolinD , RizzoM , BilbruckJ , et al. Alemtuzumab improves contrast sensitivity in patients with relapsing‐remitting multiple sclerosis. Multiple Sclerosis2013;19(10):1302‐9. ">CAMMS223 2008</a> reported alemtuzumab 12/24 mg versus IFN beta 1a at 36 months. <a href="./references#CD010968-bbs2-0002" title="ArnoldD , BrinarV , CohenJ , ColesA , ConfavreuxC , FisherE , et al. Effect of alemtuzumab vs. Rebif (registered trademark) on brain MRI measurements: results of CARE‐MS I, a phase 3 study. Neurology2012; Vol. 78, issue 1:S11.006. BalcerL , ArnoldD , CohenJ , ColesA , ConfavreuxC , FoxE , et al. Alemtuzumab improves visual outcomes in treatment‐naive patients with relapsing‐remitting multiple sclerosis (RRMS): analysis from the phase 3 CARE‐MS I study. Journal of the Neurological Sciences2013;333:e375. CohenJA , ColesAJ , ArnoldDL , ConfavreuxC , FoxEJ , HartungHP , et al. Alemtuzumab versus interferon beta 1a as first‐line treatment for patients with relapsing‐remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet2012;380(9856):1819‐28. ColesA , BrinarV , ArnoldD , CohenJ , ConfavreauxC , FoxE , et al. Efficacy and safety results from CARE‐MS I: a phase 3 study comparing alemtuzumab and interferon‐(beta)‐1a. Multiple Sclerosis2011;17(10):Suppl 510. FoxE , ArnoldD , BrinarV , CohenJ , ColesA , ConfavreuxC , et al. Relapse outcomes with alemtuzumab vs. Rebif (registered trademark) in treatment‐naive relapsing‐remitting multiple sclerosis (CARE‐MS I): secondary and tertiary endpoints. Neurology2012;78(1):Suppl PD5.004. FoxE , ArnoldD , CohenJ , ColesA , ConfavreuxC , HartungH , et al. Durable efficacy of alemtuzumab in relapsing‐remitting multiple sclerosis patients who participated in the CARE‐MS studies: three year follow‐up. Neurology2013;80(7):Suppl 41.001. GiovannoniG , ArnoldD , CohenJ , ColesA , ConfavreuxC , FoxH , et al. Disease activity‐free status in comparison of alemtuzumab and Rebif (registered trademark) efficacy in multiple sclerosis I (CARE‐MS I) phase 3 study. Journal of Neurology2012;259(1):Suppl 47. ">CARE‐MS I</a> and <a href="./references#CD010968-bbs2-0003" title="ColesAJ , TwymanCL , ArnoldDL , CohenJA , ConfavreuxC , FoxEJ , et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease‐modifying therapy: a randomised controlled phase 3 trial. Lancet2012;380(9856):1829‐39. FernandezO , ArnoldD , CohenJ , ColesA , ConfavreuxC , FoxE , et al. Alemtuzumab improves disability by month 6 independent of relapse history in relapsing‐remitting multiple sclerosis patients: CARE‐MS II. Journal of Neurology2013;260:Suppl 14. FoxE , ArnoldD , CohenJ , ColesA , ConfavreuxC , HartungH , et al. Durable efficacy of alemtuzumab in relapsing‐remitting multiple sclerosis patients who participated in the CARE‐MS studies: three year follow‐up. Neurology2013;80:Suppl 7. GiovannoniG , ArnoldD , CohenJ , ColesA , ConfavreuxC , FoxE , et al. Disability improvement with alemtuzumab vs. interferon beta‐1a in relapsing‐remitting multiple sclerosis patients who experienced disease activity while on prior therapy (CARE‐MS II). Neurology2013;80:Suppl 7. HartungH , ArnoldD , CohenJ , ColesA , ConfavreuxC , FoxE , et al. Disability outcomes for alemtuzumab in RRMS patients who relapsed on prior therapy: CARE‐MS II. Journal of Neurology2012;259(1):Suppl 47‐8. HartungH , VollmerT , ArnoldD , CohenJ , ColesA , ConfavreuxC , et al. Alemtuzumab reduces ms disease activity in active relapsing‐remitting multiple sclerosis patients who had disease activity on prior therapy. Neurology2013;80:Suppl 7. ">CARE‐MS II</a> reported alemtuzumab 12 mg versus IFN beta 1a at 24 months. In the alemtuzumab 12 mg comparison, there was significant difference in favour of alemtuzumab at 24 months (RR 0.62, 95% CI 0.53 to 0.72), 36 months (RR 0.53, 95% CI 0.35 to 0.80) and overall (RR 0.60, 95% CI 0.52 to 0.70). There was no significant heterogeneity (I² = 9%), so we applied the fixed‐effect model was applied (<a href="./references#CD010968-fig-0004" title="">Analysis 1.1</a>). Only one trial reported alemtuzumab 24 mg versus IFN beta 1a at 36 months (<a href="./references#CD010968-bbs2-0001" title="ButtonT , AltmannD , TozerD , DaltonC , CompstonD , MillerD , et al. Magnetisation transfer imaging of alemtuzumab treatment of multiple sclerosis. Multiple Sclerosis2013;19(2):241‐4. CAMMS223 Trial Investigators, ColesAJ , CompstonDA , SelmajKW , LakeSL , MoranS , MargolinDH , et al. Alemtuzumab vs. interferon beta‐1a in early multiple sclerosis. New England Journal of Medicine2008;359(17):1786‐801. ColesAJ , FoxE , VladicA , GazdaSK , BrinarV , SelmajKW , et al. Alemtuzumab more effective than interferon β‐1a at 5‐year follow‐up of CAMMS223 clinical trial. Neurology2012;78(14):1069‐78. ColesAJ , FoxE , VladicA , GazdaSK , BrinarV , SelmajKW , et al. Alemtuzumab versus interferon β‐1a in early relapsing‐remitting multiple sclerosis: post‐hoc and subset analyses of clinical efficacy outcomes. Lancet Neurology2011;10(4):338‐48. DanielsG , VladicA , BrinarV , ZavalishinI , ValenteW , OyuelaP , et al. Alemtuzumab‐related thyroid dysfunction in a phase 2 trial of patients with relapsing‐remitting multiple sclerosis. Journal of Clinical Endocrinology and Metabolism2014;99(1):80‐9. GravesJ , GalettaS , PalmerJ , MargolinD , RizzoM , BilbruckJ , et al. Alemtuzumab improves contrast sensitivity in patients with relapsing‐remitting multiple sclerosis. Multiple Sclerosis2013;19(10):1302‐9. ">CAMMS223 2008</a>). There was a significant difference in favour of alemtuzumab (RR 0.38, 95% CI 0.23 to 0.62) (see <a href="./references#CD010968-fig-0005" title="">Analysis 1.2</a>). </p> </section> <section id="CD010968-sec-0073"> <h5 class="title">Number of participants whose disease progressed at 24 and 36 months</h5> <p>All three trials assessed the number of participants who experienced disease progression at 24 and 36 months (<a href="./references#CD010968-bbs2-0001" title="ButtonT , AltmannD , TozerD , DaltonC , CompstonD , MillerD , et al. Magnetisation transfer imaging of alemtuzumab treatment of multiple sclerosis. Multiple Sclerosis2013;19(2):241‐4. CAMMS223 Trial Investigators, ColesAJ , CompstonDA , SelmajKW , LakeSL , MoranS , MargolinDH , et al. Alemtuzumab vs. interferon beta‐1a in early multiple sclerosis. New England Journal of Medicine2008;359(17):1786‐801. ColesAJ , FoxE , VladicA , GazdaSK , BrinarV , SelmajKW , et al. Alemtuzumab more effective than interferon β‐1a at 5‐year follow‐up of CAMMS223 clinical trial. Neurology2012;78(14):1069‐78. ColesAJ , FoxE , VladicA , GazdaSK , BrinarV , SelmajKW , et al. Alemtuzumab versus interferon β‐1a in early relapsing‐remitting multiple sclerosis: post‐hoc and subset analyses of clinical efficacy outcomes. Lancet Neurology2011;10(4):338‐48. DanielsG , VladicA , BrinarV , ZavalishinI , ValenteW , OyuelaP , et al. Alemtuzumab‐related thyroid dysfunction in a phase 2 trial of patients with relapsing‐remitting multiple sclerosis. Journal of Clinical Endocrinology and Metabolism2014;99(1):80‐9. GravesJ , GalettaS , PalmerJ , MargolinD , RizzoM , BilbruckJ , et al. Alemtuzumab improves contrast sensitivity in patients with relapsing‐remitting multiple sclerosis. Multiple Sclerosis2013;19(10):1302‐9. ">CAMMS223 2008</a>; <a href="./references#CD010968-bbs2-0002" title="ArnoldD , BrinarV , CohenJ , ColesA , ConfavreuxC , FisherE , et al. Effect of alemtuzumab vs. Rebif (registered trademark) on brain MRI measurements: results of CARE‐MS I, a phase 3 study. Neurology2012; Vol. 78, issue 1:S11.006. BalcerL , ArnoldD , CohenJ , ColesA , ConfavreuxC , FoxE , et al. Alemtuzumab improves visual outcomes in treatment‐naive patients with relapsing‐remitting multiple sclerosis (RRMS): analysis from the phase 3 CARE‐MS I study. Journal of the Neurological Sciences2013;333:e375. CohenJA , ColesAJ , ArnoldDL , ConfavreuxC , FoxEJ , HartungHP , et al. Alemtuzumab versus interferon beta 1a as first‐line treatment for patients with relapsing‐remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet2012;380(9856):1819‐28. ColesA , BrinarV , ArnoldD , CohenJ , ConfavreauxC , FoxE , et al. Efficacy and safety results from CARE‐MS I: a phase 3 study comparing alemtuzumab and interferon‐(beta)‐1a. Multiple Sclerosis2011;17(10):Suppl 510. FoxE , ArnoldD , BrinarV , CohenJ , ColesA , ConfavreuxC , et al. Relapse outcomes with alemtuzumab vs. Rebif (registered trademark) in treatment‐naive relapsing‐remitting multiple sclerosis (CARE‐MS I): secondary and tertiary endpoints. Neurology2012;78(1):Suppl PD5.004. FoxE , ArnoldD , CohenJ , ColesA , ConfavreuxC , HartungH , et al. Durable efficacy of alemtuzumab in relapsing‐remitting multiple sclerosis patients who participated in the CARE‐MS studies: three year follow‐up. Neurology2013;80(7):Suppl 41.001. GiovannoniG , ArnoldD , CohenJ , ColesA , ConfavreuxC , FoxH , et al. Disease activity‐free status in comparison of alemtuzumab and Rebif (registered trademark) efficacy in multiple sclerosis I (CARE‐MS I) phase 3 study. Journal of Neurology2012;259(1):Suppl 47. ">CARE‐MS I</a>; <a href="./references#CD010968-bbs2-0003" title="ColesAJ , TwymanCL , ArnoldDL , CohenJA , ConfavreuxC , FoxEJ , et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease‐modifying therapy: a randomised controlled phase 3 trial. Lancet2012;380(9856):1829‐39. FernandezO , ArnoldD , CohenJ , ColesA , ConfavreuxC , FoxE , et al. Alemtuzumab improves disability by month 6 independent of relapse history in relapsing‐remitting multiple sclerosis patients: CARE‐MS II. Journal of Neurology2013;260:Suppl 14. FoxE , ArnoldD , CohenJ , ColesA , ConfavreuxC , HartungH , et al. Durable efficacy of alemtuzumab in relapsing‐remitting multiple sclerosis patients who participated in the CARE‐MS studies: three year follow‐up. Neurology2013;80:Suppl 7. GiovannoniG , ArnoldD , CohenJ , ColesA , ConfavreuxC , FoxE , et al. Disability improvement with alemtuzumab vs. interferon beta‐1a in relapsing‐remitting multiple sclerosis patients who experienced disease activity while on prior therapy (CARE‐MS II). Neurology2013;80:Suppl 7. HartungH , ArnoldD , CohenJ , ColesA , ConfavreuxC , FoxE , et al. Disability outcomes for alemtuzumab in RRMS patients who relapsed on prior therapy: CARE‐MS II. Journal of Neurology2012;259(1):Suppl 47‐8. HartungH , VollmerT , ArnoldD , CohenJ , ColesA , ConfavreuxC , et al. Alemtuzumab reduces ms disease activity in active relapsing‐remitting multiple sclerosis patients who had disease activity on prior therapy. Neurology2013;80:Suppl 7. ">CARE‐MS II</a>). </p> <p><a href="./references#CD010968-bbs2-0001" title="ButtonT , AltmannD , TozerD , DaltonC , CompstonD , MillerD , et al. Magnetisation transfer imaging of alemtuzumab treatment of multiple sclerosis. Multiple Sclerosis2013;19(2):241‐4. CAMMS223 Trial Investigators, ColesAJ , CompstonDA , SelmajKW , LakeSL , MoranS , MargolinDH , et al. Alemtuzumab vs. interferon beta‐1a in early multiple sclerosis. New England Journal of Medicine2008;359(17):1786‐801. ColesAJ , FoxE , VladicA , GazdaSK , BrinarV , SelmajKW , et al. Alemtuzumab more effective than interferon β‐1a at 5‐year follow‐up of CAMMS223 clinical trial. Neurology2012;78(14):1069‐78. ColesAJ , FoxE , VladicA , GazdaSK , BrinarV , SelmajKW , et al. Alemtuzumab versus interferon β‐1a in early relapsing‐remitting multiple sclerosis: post‐hoc and subset analyses of clinical efficacy outcomes. Lancet Neurology2011;10(4):338‐48. DanielsG , VladicA , BrinarV , ZavalishinI , ValenteW , OyuelaP , et al. Alemtuzumab‐related thyroid dysfunction in a phase 2 trial of patients with relapsing‐remitting multiple sclerosis. Journal of Clinical Endocrinology and Metabolism2014;99(1):80‐9. GravesJ , GalettaS , PalmerJ , MargolinD , RizzoM , BilbruckJ , et al. Alemtuzumab improves contrast sensitivity in patients with relapsing‐remitting multiple sclerosis. Multiple Sclerosis2013;19(10):1302‐9. ">CAMMS223 2008</a> reported alemtuzumab 12/24 mg versus IFN beta 1a at 36 months; <a href="./references#CD010968-bbs2-0002" title="ArnoldD , BrinarV , CohenJ , ColesA , ConfavreuxC , FisherE , et al. Effect of alemtuzumab vs. Rebif (registered trademark) on brain MRI measurements: results of CARE‐MS I, a phase 3 study. Neurology2012; Vol. 78, issue 1:S11.006. BalcerL , ArnoldD , CohenJ , ColesA , ConfavreuxC , FoxE , et al. Alemtuzumab improves visual outcomes in treatment‐naive patients with relapsing‐remitting multiple sclerosis (RRMS): analysis from the phase 3 CARE‐MS I study. Journal of the Neurological Sciences2013;333:e375. CohenJA , ColesAJ , ArnoldDL , ConfavreuxC , FoxEJ , HartungHP , et al. Alemtuzumab versus interferon beta 1a as first‐line treatment for patients with relapsing‐remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet2012;380(9856):1819‐28. ColesA , BrinarV , ArnoldD , CohenJ , ConfavreauxC , FoxE , et al. Efficacy and safety results from CARE‐MS I: a phase 3 study comparing alemtuzumab and interferon‐(beta)‐1a. Multiple Sclerosis2011;17(10):Suppl 510. FoxE , ArnoldD , BrinarV , CohenJ , ColesA , ConfavreuxC , et al. Relapse outcomes with alemtuzumab vs. Rebif (registered trademark) in treatment‐naive relapsing‐remitting multiple sclerosis (CARE‐MS I): secondary and tertiary endpoints. Neurology2012;78(1):Suppl PD5.004. FoxE , ArnoldD , CohenJ , ColesA , ConfavreuxC , HartungH , et al. Durable efficacy of alemtuzumab in relapsing‐remitting multiple sclerosis patients who participated in the CARE‐MS studies: three year follow‐up. Neurology2013;80(7):Suppl 41.001. GiovannoniG , ArnoldD , CohenJ , ColesA , ConfavreuxC , FoxH , et al. Disease activity‐free status in comparison of alemtuzumab and Rebif (registered trademark) efficacy in multiple sclerosis I (CARE‐MS I) phase 3 study. Journal of Neurology2012;259(1):Suppl 47. ">CARE‐MS I</a> and <a href="./references#CD010968-bbs2-0003" title="ColesAJ , TwymanCL , ArnoldDL , CohenJA , ConfavreuxC , FoxEJ , et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease‐modifying therapy: a randomised controlled phase 3 trial. Lancet2012;380(9856):1829‐39. FernandezO , ArnoldD , CohenJ , ColesA , ConfavreuxC , FoxE , et al. Alemtuzumab improves disability by month 6 independent of relapse history in relapsing‐remitting multiple sclerosis patients: CARE‐MS II. Journal of Neurology2013;260:Suppl 14. FoxE , ArnoldD , CohenJ , ColesA , ConfavreuxC , HartungH , et al. Durable efficacy of alemtuzumab in relapsing‐remitting multiple sclerosis patients who participated in the CARE‐MS studies: three year follow‐up. Neurology2013;80:Suppl 7. GiovannoniG , ArnoldD , CohenJ , ColesA , ConfavreuxC , FoxE , et al. Disability improvement with alemtuzumab vs. interferon beta‐1a in relapsing‐remitting multiple sclerosis patients who experienced disease activity while on prior therapy (CARE‐MS II). Neurology2013;80:Suppl 7. HartungH , ArnoldD , CohenJ , ColesA , ConfavreuxC , FoxE , et al. Disability outcomes for alemtuzumab in RRMS patients who relapsed on prior therapy: CARE‐MS II. Journal of Neurology2012;259(1):Suppl 47‐8. HartungH , VollmerT , ArnoldD , CohenJ , ColesA , ConfavreuxC , et al. Alemtuzumab reduces ms disease activity in active relapsing‐remitting multiple sclerosis patients who had disease activity on prior therapy. Neurology2013;80:Suppl 7. ">CARE‐MS II</a> reported alemtuzumab 12 mg versus IFN beta 1a at 24 months. In the alemtuzumab 12 mg comparison, there was significant difference in favour of alemtuzumab at 24 months (RR 0.68, 95% CI 0.50 to 0.92), 36 months (RR 0.33, 95% CI 0.16 to 0.70) and overall (RR 0.60, 95% CI 0.45 to 0.79). There was no significant heterogeneity (I² = 37%), therefore, we applied the fixed‐effect model (<a href="./references#CD010968-fig-0006" title="">Analysis 2.1</a>). One trial reported alemtuzumab 24 mg versus IFN beta 1a (<a href="./references#CD010968-bbs2-0001" title="ButtonT , AltmannD , TozerD , DaltonC , CompstonD , MillerD , et al. Magnetisation transfer imaging of alemtuzumab treatment of multiple sclerosis. Multiple Sclerosis2013;19(2):241‐4. CAMMS223 Trial Investigators, ColesAJ , CompstonDA , SelmajKW , LakeSL , MoranS , MargolinDH , et al. Alemtuzumab vs. interferon beta‐1a in early multiple sclerosis. New England Journal of Medicine2008;359(17):1786‐801. ColesAJ , FoxE , VladicA , GazdaSK , BrinarV , SelmajKW , et al. Alemtuzumab more effective than interferon β‐1a at 5‐year follow‐up of CAMMS223 clinical trial. Neurology2012;78(14):1069‐78. ColesAJ , FoxE , VladicA , GazdaSK , BrinarV , SelmajKW , et al. Alemtuzumab versus interferon β‐1a in early relapsing‐remitting multiple sclerosis: post‐hoc and subset analyses of clinical efficacy outcomes. Lancet Neurology2011;10(4):338‐48. DanielsG , VladicA , BrinarV , ZavalishinI , ValenteW , OyuelaP , et al. Alemtuzumab‐related thyroid dysfunction in a phase 2 trial of patients with relapsing‐remitting multiple sclerosis. Journal of Clinical Endocrinology and Metabolism2014;99(1):80‐9. GravesJ , GalettaS , PalmerJ , MargolinD , RizzoM , BilbruckJ , et al. Alemtuzumab improves contrast sensitivity in patients with relapsing‐remitting multiple sclerosis. Multiple Sclerosis2013;19(10):1302‐9. ">CAMMS223 2008</a>). There was significant difference in favour of alemtuzumab at 36 months (RR 0.42, 95% CI 0.21 to 0.84) (<a href="./references#CD010968-fig-0007" title="">Analysis 2.2</a>). </p> </section> <section id="CD010968-sec-0074"> <h5 class="title">Number of participants with at least one adverse event, including serious adverse events </h5> <p>All three trials reported adverse events and serious adverse events (<a href="./references#CD010968-bbs2-0001" title="ButtonT , AltmannD , TozerD , DaltonC , CompstonD , MillerD , et al. Magnetisation transfer imaging of alemtuzumab treatment of multiple sclerosis. Multiple Sclerosis2013;19(2):241‐4. CAMMS223 Trial Investigators, ColesAJ , CompstonDA , SelmajKW , LakeSL , MoranS , MargolinDH , et al. Alemtuzumab vs. interferon beta‐1a in early multiple sclerosis. New England Journal of Medicine2008;359(17):1786‐801. ColesAJ , FoxE , VladicA , GazdaSK , BrinarV , SelmajKW , et al. Alemtuzumab more effective than interferon β‐1a at 5‐year follow‐up of CAMMS223 clinical trial. Neurology2012;78(14):1069‐78. ColesAJ , FoxE , VladicA , GazdaSK , BrinarV , SelmajKW , et al. Alemtuzumab versus interferon β‐1a in early relapsing‐remitting multiple sclerosis: post‐hoc and subset analyses of clinical efficacy outcomes. Lancet Neurology2011;10(4):338‐48. DanielsG , VladicA , BrinarV , ZavalishinI , ValenteW , OyuelaP , et al. Alemtuzumab‐related thyroid dysfunction in a phase 2 trial of patients with relapsing‐remitting multiple sclerosis. Journal of Clinical Endocrinology and Metabolism2014;99(1):80‐9. GravesJ , GalettaS , PalmerJ , MargolinD , RizzoM , BilbruckJ , et al. Alemtuzumab improves contrast sensitivity in patients with relapsing‐remitting multiple sclerosis. Multiple Sclerosis2013;19(10):1302‐9. ">CAMMS223 2008</a>; <a href="./references#CD010968-bbs2-0002" title="ArnoldD , BrinarV , CohenJ , ColesA , ConfavreuxC , FisherE , et al. Effect of alemtuzumab vs. Rebif (registered trademark) on brain MRI measurements: results of CARE‐MS I, a phase 3 study. Neurology2012; Vol. 78, issue 1:S11.006. BalcerL , ArnoldD , CohenJ , ColesA , ConfavreuxC , FoxE , et al. Alemtuzumab improves visual outcomes in treatment‐naive patients with relapsing‐remitting multiple sclerosis (RRMS): analysis from the phase 3 CARE‐MS I study. Journal of the Neurological Sciences2013;333:e375. CohenJA , ColesAJ , ArnoldDL , ConfavreuxC , FoxEJ , HartungHP , et al. Alemtuzumab versus interferon beta 1a as first‐line treatment for patients with relapsing‐remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet2012;380(9856):1819‐28. ColesA , BrinarV , ArnoldD , CohenJ , ConfavreauxC , FoxE , et al. Efficacy and safety results from CARE‐MS I: a phase 3 study comparing alemtuzumab and interferon‐(beta)‐1a. Multiple Sclerosis2011;17(10):Suppl 510. FoxE , ArnoldD , BrinarV , CohenJ , ColesA , ConfavreuxC , et al. Relapse outcomes with alemtuzumab vs. Rebif (registered trademark) in treatment‐naive relapsing‐remitting multiple sclerosis (CARE‐MS I): secondary and tertiary endpoints. Neurology2012;78(1):Suppl PD5.004. FoxE , ArnoldD , CohenJ , ColesA , ConfavreuxC , HartungH , et al. Durable efficacy of alemtuzumab in relapsing‐remitting multiple sclerosis patients who participated in the CARE‐MS studies: three year follow‐up. Neurology2013;80(7):Suppl 41.001. GiovannoniG , ArnoldD , CohenJ , ColesA , ConfavreuxC , FoxH , et al. Disease activity‐free status in comparison of alemtuzumab and Rebif (registered trademark) efficacy in multiple sclerosis I (CARE‐MS I) phase 3 study. Journal of Neurology2012;259(1):Suppl 47. ">CARE‐MS I</a>; <a href="./references#CD010968-bbs2-0003" title="ColesAJ , TwymanCL , ArnoldDL , CohenJA , ConfavreuxC , FoxEJ , et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease‐modifying therapy: a randomised controlled phase 3 trial. Lancet2012;380(9856):1829‐39. FernandezO , ArnoldD , CohenJ , ColesA , ConfavreuxC , FoxE , et al. Alemtuzumab improves disability by month 6 independent of relapse history in relapsing‐remitting multiple sclerosis patients: CARE‐MS II. Journal of Neurology2013;260:Suppl 14. FoxE , ArnoldD , CohenJ , ColesA , ConfavreuxC , HartungH , et al. Durable efficacy of alemtuzumab in relapsing‐remitting multiple sclerosis patients who participated in the CARE‐MS studies: three year follow‐up. Neurology2013;80:Suppl 7. GiovannoniG , ArnoldD , CohenJ , ColesA , ConfavreuxC , FoxE , et al. Disability improvement with alemtuzumab vs. interferon beta‐1a in relapsing‐remitting multiple sclerosis patients who experienced disease activity while on prior therapy (CARE‐MS II). Neurology2013;80:Suppl 7. HartungH , ArnoldD , CohenJ , ColesA , ConfavreuxC , FoxE , et al. Disability outcomes for alemtuzumab in RRMS patients who relapsed on prior therapy: CARE‐MS II. Journal of Neurology2012;259(1):Suppl 47‐8. HartungH , VollmerT , ArnoldD , CohenJ , ColesA , ConfavreuxC , et al. Alemtuzumab reduces ms disease activity in active relapsing‐remitting multiple sclerosis patients who had disease activity on prior therapy. Neurology2013;80:Suppl 7. ">CARE‐MS II</a>). </p> <p><a href="./references#CD010968-bbs2-0001" title="ButtonT , AltmannD , TozerD , DaltonC , CompstonD , MillerD , et al. Magnetisation transfer imaging of alemtuzumab treatment of multiple sclerosis. Multiple Sclerosis2013;19(2):241‐4. CAMMS223 Trial Investigators, ColesAJ , CompstonDA , SelmajKW , LakeSL , MoranS , MargolinDH , et al. Alemtuzumab vs. interferon beta‐1a in early multiple sclerosis. New England Journal of Medicine2008;359(17):1786‐801. ColesAJ , FoxE , VladicA , GazdaSK , BrinarV , SelmajKW , et al. Alemtuzumab more effective than interferon β‐1a at 5‐year follow‐up of CAMMS223 clinical trial. Neurology2012;78(14):1069‐78. ColesAJ , FoxE , VladicA , GazdaSK , BrinarV , SelmajKW , et al. Alemtuzumab versus interferon β‐1a in early relapsing‐remitting multiple sclerosis: post‐hoc and subset analyses of clinical efficacy outcomes. Lancet Neurology2011;10(4):338‐48. DanielsG , VladicA , BrinarV , ZavalishinI , ValenteW , OyuelaP , et al. Alemtuzumab‐related thyroid dysfunction in a phase 2 trial of patients with relapsing‐remitting multiple sclerosis. Journal of Clinical Endocrinology and Metabolism2014;99(1):80‐9. GravesJ , GalettaS , PalmerJ , MargolinD , RizzoM , BilbruckJ , et al. Alemtuzumab improves contrast sensitivity in patients with relapsing‐remitting multiple sclerosis. Multiple Sclerosis2013;19(10):1302‐9. ">CAMMS223 2008</a> reported alemtuzumab 12/24 mg versus IFN beta 1a at 36 months; <a href="./references#CD010968-bbs2-0002" title="ArnoldD , BrinarV , CohenJ , ColesA , ConfavreuxC , FisherE , et al. Effect of alemtuzumab vs. Rebif (registered trademark) on brain MRI measurements: results of CARE‐MS I, a phase 3 study. Neurology2012; Vol. 78, issue 1:S11.006. BalcerL , ArnoldD , CohenJ , ColesA , ConfavreuxC , FoxE , et al. Alemtuzumab improves visual outcomes in treatment‐naive patients with relapsing‐remitting multiple sclerosis (RRMS): analysis from the phase 3 CARE‐MS I study. Journal of the Neurological Sciences2013;333:e375. CohenJA , ColesAJ , ArnoldDL , ConfavreuxC , FoxEJ , HartungHP , et al. Alemtuzumab versus interferon beta 1a as first‐line treatment for patients with relapsing‐remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet2012;380(9856):1819‐28. ColesA , BrinarV , ArnoldD , CohenJ , ConfavreauxC , FoxE , et al. Efficacy and safety results from CARE‐MS I: a phase 3 study comparing alemtuzumab and interferon‐(beta)‐1a. Multiple Sclerosis2011;17(10):Suppl 510. FoxE , ArnoldD , BrinarV , CohenJ , ColesA , ConfavreuxC , et al. Relapse outcomes with alemtuzumab vs. Rebif (registered trademark) in treatment‐naive relapsing‐remitting multiple sclerosis (CARE‐MS I): secondary and tertiary endpoints. Neurology2012;78(1):Suppl PD5.004. FoxE , ArnoldD , CohenJ , ColesA , ConfavreuxC , HartungH , et al. Durable efficacy of alemtuzumab in relapsing‐remitting multiple sclerosis patients who participated in the CARE‐MS studies: three year follow‐up. Neurology2013;80(7):Suppl 41.001. GiovannoniG , ArnoldD , CohenJ , ColesA , ConfavreuxC , FoxH , et al. Disease activity‐free status in comparison of alemtuzumab and Rebif (registered trademark) efficacy in multiple sclerosis I (CARE‐MS I) phase 3 study. Journal of Neurology2012;259(1):Suppl 47. ">CARE‐MS I</a> reported alemtuzumab 12 mg versus IFN beta 1a at 24 months; and <a href="./references#CD010968-bbs2-0003" title="ColesAJ , TwymanCL , ArnoldDL , CohenJA , ConfavreuxC , FoxEJ , et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease‐modifying therapy: a randomised controlled phase 3 trial. Lancet2012;380(9856):1829‐39. FernandezO , ArnoldD , CohenJ , ColesA , ConfavreuxC , FoxE , et al. Alemtuzumab improves disability by month 6 independent of relapse history in relapsing‐remitting multiple sclerosis patients: CARE‐MS II. Journal of Neurology2013;260:Suppl 14. FoxE , ArnoldD , CohenJ , ColesA , ConfavreuxC , HartungH , et al. Durable efficacy of alemtuzumab in relapsing‐remitting multiple sclerosis patients who participated in the CARE‐MS studies: three year follow‐up. Neurology2013;80:Suppl 7. GiovannoniG , ArnoldD , CohenJ , ColesA , ConfavreuxC , FoxE , et al. Disability improvement with alemtuzumab vs. interferon beta‐1a in relapsing‐remitting multiple sclerosis patients who experienced disease activity while on prior therapy (CARE‐MS II). Neurology2013;80:Suppl 7. HartungH , ArnoldD , CohenJ , ColesA , ConfavreuxC , FoxE , et al. Disability outcomes for alemtuzumab in RRMS patients who relapsed on prior therapy: CARE‐MS II. Journal of Neurology2012;259(1):Suppl 47‐8. HartungH , VollmerT , ArnoldD , CohenJ , ColesA , ConfavreuxC , et al. Alemtuzumab reduces ms disease activity in active relapsing‐remitting multiple sclerosis patients who had disease activity on prior therapy. Neurology2013;80:Suppl 7. ">CARE‐MS II</a> reported alemtuzumab 12/24 mg versus IFN beta 1a at 24 months. </p> <p>In the alemtuzumab 12 mg group, 897/919 (98%) participants experienced any adverse event and in the IFN beta 1a group, 470/496 (95%) participants experienced any adverse events (RR 1.03, 95% CI 0.98 to 1.08) (<a href="./references#CD010968-fig-0008" title="">Analysis 3.1</a>). In the alemtuzumab 12 mg group, 178/919 (19.3%) participants experienced serious adverse events and in the IFN beta 1a group, 95/496 (19.2%) participants experienced serious adverse events (RR 1.03, 95% CI 0.82 to 1.29) (<a href="./references#CD010968-fig-0010" title="">Analysis 4.1</a>). </p> <p>In the alemtuzumab 24 mg group, 266/269 (99%) participants experienced any adverse event and in the IFN beta 1a group, 298/309 (96%) participants experienced any adverse events (RR 1.02, 95% CI 0.96 to 1.08) (<a href="./references#CD010968-fig-0009" title="">Analysis 3.2</a>). In the alemtuzumab 24 mg group, 57/269 (21.2%) participants experienced serious adverse events and in the IFN beta 1a group, 68/309 (22.0%) participants experienced serious adverse events (RR 0.95, 95% CI 0.70 to 1.31) (<a href="./references#CD010968-fig-0011" title="">Analysis 4.2</a>). </p> </section> </section> <section id="CD010968-sec-0075"> <h4 class="title">Secondary outcomes</h4> <section id="CD010968-sec-0076"> <h5 class="title">Mean EDSS score change from baseline at 24 and 36 months</h5> <p>All three trials reported mean EDSS score change from baseline at 24 and 36 months (<a href="./references#CD010968-bbs2-0001" title="ButtonT , AltmannD , TozerD , DaltonC , CompstonD , MillerD , et al. Magnetisation transfer imaging of alemtuzumab treatment of multiple sclerosis. Multiple Sclerosis2013;19(2):241‐4. CAMMS223 Trial Investigators, ColesAJ , CompstonDA , SelmajKW , LakeSL , MoranS , MargolinDH , et al. Alemtuzumab vs. interferon beta‐1a in early multiple sclerosis. New England Journal of Medicine2008;359(17):1786‐801. ColesAJ , FoxE , VladicA , GazdaSK , BrinarV , SelmajKW , et al. Alemtuzumab more effective than interferon β‐1a at 5‐year follow‐up of CAMMS223 clinical trial. Neurology2012;78(14):1069‐78. ColesAJ , FoxE , VladicA , GazdaSK , BrinarV , SelmajKW , et al. Alemtuzumab versus interferon β‐1a in early relapsing‐remitting multiple sclerosis: post‐hoc and subset analyses of clinical efficacy outcomes. Lancet Neurology2011;10(4):338‐48. DanielsG , VladicA , BrinarV , ZavalishinI , ValenteW , OyuelaP , et al. Alemtuzumab‐related thyroid dysfunction in a phase 2 trial of patients with relapsing‐remitting multiple sclerosis. Journal of Clinical Endocrinology and Metabolism2014;99(1):80‐9. GravesJ , GalettaS , PalmerJ , MargolinD , RizzoM , BilbruckJ , et al. Alemtuzumab improves contrast sensitivity in patients with relapsing‐remitting multiple sclerosis. Multiple Sclerosis2013;19(10):1302‐9. ">CAMMS223 2008</a>; <a href="./references#CD010968-bbs2-0002" title="ArnoldD , BrinarV , CohenJ , ColesA , ConfavreuxC , FisherE , et al. Effect of alemtuzumab vs. Rebif (registered trademark) on brain MRI measurements: results of CARE‐MS I, a phase 3 study. Neurology2012; Vol. 78, issue 1:S11.006. BalcerL , ArnoldD , CohenJ , ColesA , ConfavreuxC , FoxE , et al. Alemtuzumab improves visual outcomes in treatment‐naive patients with relapsing‐remitting multiple sclerosis (RRMS): analysis from the phase 3 CARE‐MS I study. Journal of the Neurological Sciences2013;333:e375. CohenJA , ColesAJ , ArnoldDL , ConfavreuxC , FoxEJ , HartungHP , et al. Alemtuzumab versus interferon beta 1a as first‐line treatment for patients with relapsing‐remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet2012;380(9856):1819‐28. ColesA , BrinarV , ArnoldD , CohenJ , ConfavreauxC , FoxE , et al. Efficacy and safety results from CARE‐MS I: a phase 3 study comparing alemtuzumab and interferon‐(beta)‐1a. Multiple Sclerosis2011;17(10):Suppl 510. FoxE , ArnoldD , BrinarV , CohenJ , ColesA , ConfavreuxC , et al. Relapse outcomes with alemtuzumab vs. Rebif (registered trademark) in treatment‐naive relapsing‐remitting multiple sclerosis (CARE‐MS I): secondary and tertiary endpoints. Neurology2012;78(1):Suppl PD5.004. FoxE , ArnoldD , CohenJ , ColesA , ConfavreuxC , HartungH , et al. Durable efficacy of alemtuzumab in relapsing‐remitting multiple sclerosis patients who participated in the CARE‐MS studies: three year follow‐up. Neurology2013;80(7):Suppl 41.001. GiovannoniG , ArnoldD , CohenJ , ColesA , ConfavreuxC , FoxH , et al. Disease activity‐free status in comparison of alemtuzumab and Rebif (registered trademark) efficacy in multiple sclerosis I (CARE‐MS I) phase 3 study. Journal of Neurology2012;259(1):Suppl 47. ">CARE‐MS I</a>; <a href="./references#CD010968-bbs2-0003" title="ColesAJ , TwymanCL , ArnoldDL , CohenJA , ConfavreuxC , FoxEJ , et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease‐modifying therapy: a randomised controlled phase 3 trial. Lancet2012;380(9856):1829‐39. FernandezO , ArnoldD , CohenJ , ColesA , ConfavreuxC , FoxE , et al. Alemtuzumab improves disability by month 6 independent of relapse history in relapsing‐remitting multiple sclerosis patients: CARE‐MS II. Journal of Neurology2013;260:Suppl 14. FoxE , ArnoldD , CohenJ , ColesA , ConfavreuxC , HartungH , et al. Durable efficacy of alemtuzumab in relapsing‐remitting multiple sclerosis patients who participated in the CARE‐MS studies: three year follow‐up. Neurology2013;80:Suppl 7. GiovannoniG , ArnoldD , CohenJ , ColesA , ConfavreuxC , FoxE , et al. Disability improvement with alemtuzumab vs. interferon beta‐1a in relapsing‐remitting multiple sclerosis patients who experienced disease activity while on prior therapy (CARE‐MS II). Neurology2013;80:Suppl 7. HartungH , ArnoldD , CohenJ , ColesA , ConfavreuxC , FoxE , et al. Disability outcomes for alemtuzumab in RRMS patients who relapsed on prior therapy: CARE‐MS II. Journal of Neurology2012;259(1):Suppl 47‐8. HartungH , VollmerT , ArnoldD , CohenJ , ColesA , ConfavreuxC , et al. Alemtuzumab reduces ms disease activity in active relapsing‐remitting multiple sclerosis patients who had disease activity on prior therapy. Neurology2013;80:Suppl 7. ">CARE‐MS II</a>). </p> <p>CAMMS223 2008 reported alemtuzumab 12/24 mg versus IFN beta 1a at 36 months. CARE‐MS I and CARE‐MS II reported alemtuzumab 12 mg versus IFN beta 1a at 24 months. Evidence for an effect of decreased disability worsening, as measured by the Expanded Disability Status Scale (EDSS) with alemtuzumab 12 mg compared with IFN beta 1a at 24 months in two studies, was imprecise and with high level of statistical heterogeneity (MD ‐0.20, 95% CI ‐0.60 to 0.20; I<sup>2</sup>=88%; Analysis 5.1.1). EDSS was reported by <a href="https://archie.cochrane.org/sections/documents/view?version=z1803061530561122876904187796509%26format=REVMAN#STD-CAMMS223-2008" target="_blank">CAMMS223 2008</a> that found significant difference in favour of alemtuzumab 12 mg compared to IFB beta 1a at 36 months of treatment (MD ‐0.70, 95% CI ‐1.04 to ‐0.36; Analysis 5.1.2). The pooled result did not favour alemtuzumab 12 mg compared to IFN beta 1a ( MD ‐0.35, 95% CI ‐0.73 to 0.03; <a href="./references#CD010968-fig-0012" title="">Analysis 5.1</a>; <a href="./full#CD010968-tbl-0001">summary of findings Table for the main comparison</a>). One trial comparing alemtuzumab 24 mg versus IFN beta 1a (<a href="https://archie.cochrane.org/sections/documents/view?version=z1803061530561122876904187796509%26format=REVMAN#STD-CAMMS223-2008" target="_blank">CAMMS223 2008</a>) found significant difference in favour of alemtuzumab at 36 months but with a wide confidence interval (MD ‐0.83, 95% CI ‐1.17 to ‐0.49; <a href="https://archie.cochrane.org/sections/documents/view?version=z1803061530561122876904187796509%26format=REVMAN#CMP-005.02" target="_blank">Analysis 5.2</a>). </p> </section> <section id="CD010968-sec-0077"> <h5 class="title">Number of participants with new T2‐hyperintense lesions on magnetic resonance imaging at 24 and 36 months </h5> <p>Two trials reported the number of participants with new T2‐hyperintense lesions on MRI at 24 and 36 months (<a href="./references#CD010968-bbs2-0002" title="ArnoldD , BrinarV , CohenJ , ColesA , ConfavreuxC , FisherE , et al. Effect of alemtuzumab vs. Rebif (registered trademark) on brain MRI measurements: results of CARE‐MS I, a phase 3 study. Neurology2012; Vol. 78, issue 1:S11.006. BalcerL , ArnoldD , CohenJ , ColesA , ConfavreuxC , FoxE , et al. Alemtuzumab improves visual outcomes in treatment‐naive patients with relapsing‐remitting multiple sclerosis (RRMS): analysis from the phase 3 CARE‐MS I study. Journal of the Neurological Sciences2013;333:e375. CohenJA , ColesAJ , ArnoldDL , ConfavreuxC , FoxEJ , HartungHP , et al. Alemtuzumab versus interferon beta 1a as first‐line treatment for patients with relapsing‐remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet2012;380(9856):1819‐28. ColesA , BrinarV , ArnoldD , CohenJ , ConfavreauxC , FoxE , et al. Efficacy and safety results from CARE‐MS I: a phase 3 study comparing alemtuzumab and interferon‐(beta)‐1a. Multiple Sclerosis2011;17(10):Suppl 510. FoxE , ArnoldD , BrinarV , CohenJ , ColesA , ConfavreuxC , et al. Relapse outcomes with alemtuzumab vs. Rebif (registered trademark) in treatment‐naive relapsing‐remitting multiple sclerosis (CARE‐MS I): secondary and tertiary endpoints. Neurology2012;78(1):Suppl PD5.004. FoxE , ArnoldD , CohenJ , ColesA , ConfavreuxC , HartungH , et al. Durable efficacy of alemtuzumab in relapsing‐remitting multiple sclerosis patients who participated in the CARE‐MS studies: three year follow‐up. Neurology2013;80(7):Suppl 41.001. GiovannoniG , ArnoldD , CohenJ , ColesA , ConfavreuxC , FoxH , et al. Disease activity‐free status in comparison of alemtuzumab and Rebif (registered trademark) efficacy in multiple sclerosis I (CARE‐MS I) phase 3 study. Journal of Neurology2012;259(1):Suppl 47. ">CARE‐MS I</a>; <a href="./references#CD010968-bbs2-0003" title="ColesAJ , TwymanCL , ArnoldDL , CohenJA , ConfavreuxC , FoxEJ , et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease‐modifying therapy: a randomised controlled phase 3 trial. Lancet2012;380(9856):1829‐39. FernandezO , ArnoldD , CohenJ , ColesA , ConfavreuxC , FoxE , et al. Alemtuzumab improves disability by month 6 independent of relapse history in relapsing‐remitting multiple sclerosis patients: CARE‐MS II. Journal of Neurology2013;260:Suppl 14. FoxE , ArnoldD , CohenJ , ColesA , ConfavreuxC , HartungH , et al. Durable efficacy of alemtuzumab in relapsing‐remitting multiple sclerosis patients who participated in the CARE‐MS studies: three year follow‐up. Neurology2013;80:Suppl 7. GiovannoniG , ArnoldD , CohenJ , ColesA , ConfavreuxC , FoxE , et al. Disability improvement with alemtuzumab vs. interferon beta‐1a in relapsing‐remitting multiple sclerosis patients who experienced disease activity while on prior therapy (CARE‐MS II). Neurology2013;80:Suppl 7. HartungH , ArnoldD , CohenJ , ColesA , ConfavreuxC , FoxE , et al. Disability outcomes for alemtuzumab in RRMS patients who relapsed on prior therapy: CARE‐MS II. Journal of Neurology2012;259(1):Suppl 47‐8. HartungH , VollmerT , ArnoldD , CohenJ , ColesA , ConfavreuxC , et al. Alemtuzumab reduces ms disease activity in active relapsing‐remitting multiple sclerosis patients who had disease activity on prior therapy. Neurology2013;80:Suppl 7. ">CARE‐MS II</a>). There was significant difference in developing new T2 lesions on MRI favouring alemtuzumab 12 mg at 24 months (RR 0.75, 95% CI 0.61 to 0.93) (<a href="./references#CD010968-fig-0014" title="">Analysis 6.1</a>). There was significant heterogeneity (I² = 73%), so we applied the random‐effects model). </p> </section> <section id="CD010968-sec-0078"> <h5 class="title">Number of participants experiencing treatment discontinuation caused by adverse events</h5> <p>All three trials reported the number of participants experiencing treatment discontinuation caused by adverse events (<a href="./references#CD010968-bbs2-0001" title="ButtonT , AltmannD , TozerD , DaltonC , CompstonD , MillerD , et al. Magnetisation transfer imaging of alemtuzumab treatment of multiple sclerosis. Multiple Sclerosis2013;19(2):241‐4. CAMMS223 Trial Investigators, ColesAJ , CompstonDA , SelmajKW , LakeSL , MoranS , MargolinDH , et al. Alemtuzumab vs. interferon beta‐1a in early multiple sclerosis. New England Journal of Medicine2008;359(17):1786‐801. ColesAJ , FoxE , VladicA , GazdaSK , BrinarV , SelmajKW , et al. Alemtuzumab more effective than interferon β‐1a at 5‐year follow‐up of CAMMS223 clinical trial. Neurology2012;78(14):1069‐78. ColesAJ , FoxE , VladicA , GazdaSK , BrinarV , SelmajKW , et al. Alemtuzumab versus interferon β‐1a in early relapsing‐remitting multiple sclerosis: post‐hoc and subset analyses of clinical efficacy outcomes. Lancet Neurology2011;10(4):338‐48. DanielsG , VladicA , BrinarV , ZavalishinI , ValenteW , OyuelaP , et al. Alemtuzumab‐related thyroid dysfunction in a phase 2 trial of patients with relapsing‐remitting multiple sclerosis. Journal of Clinical Endocrinology and Metabolism2014;99(1):80‐9. GravesJ , GalettaS , PalmerJ , MargolinD , RizzoM , BilbruckJ , et al. Alemtuzumab improves contrast sensitivity in patients with relapsing‐remitting multiple sclerosis. Multiple Sclerosis2013;19(10):1302‐9. ">CAMMS223 2008</a>; <a href="./references#CD010968-bbs2-0002" title="ArnoldD , BrinarV , CohenJ , ColesA , ConfavreuxC , FisherE , et al. Effect of alemtuzumab vs. Rebif (registered trademark) on brain MRI measurements: results of CARE‐MS I, a phase 3 study. Neurology2012; Vol. 78, issue 1:S11.006. BalcerL , ArnoldD , CohenJ , ColesA , ConfavreuxC , FoxE , et al. Alemtuzumab improves visual outcomes in treatment‐naive patients with relapsing‐remitting multiple sclerosis (RRMS): analysis from the phase 3 CARE‐MS I study. Journal of the Neurological Sciences2013;333:e375. CohenJA , ColesAJ , ArnoldDL , ConfavreuxC , FoxEJ , HartungHP , et al. Alemtuzumab versus interferon beta 1a as first‐line treatment for patients with relapsing‐remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet2012;380(9856):1819‐28. ColesA , BrinarV , ArnoldD , CohenJ , ConfavreauxC , FoxE , et al. Efficacy and safety results from CARE‐MS I: a phase 3 study comparing alemtuzumab and interferon‐(beta)‐1a. Multiple Sclerosis2011;17(10):Suppl 510. FoxE , ArnoldD , BrinarV , CohenJ , ColesA , ConfavreuxC , et al. Relapse outcomes with alemtuzumab vs. Rebif (registered trademark) in treatment‐naive relapsing‐remitting multiple sclerosis (CARE‐MS I): secondary and tertiary endpoints. Neurology2012;78(1):Suppl PD5.004. FoxE , ArnoldD , CohenJ , ColesA , ConfavreuxC , HartungH , et al. Durable efficacy of alemtuzumab in relapsing‐remitting multiple sclerosis patients who participated in the CARE‐MS studies: three year follow‐up. Neurology2013;80(7):Suppl 41.001. GiovannoniG , ArnoldD , CohenJ , ColesA , ConfavreuxC , FoxH , et al. Disease activity‐free status in comparison of alemtuzumab and Rebif (registered trademark) efficacy in multiple sclerosis I (CARE‐MS I) phase 3 study. Journal of Neurology2012;259(1):Suppl 47. ">CARE‐MS I</a>; <a href="./references#CD010968-bbs2-0003" title="ColesAJ , TwymanCL , ArnoldDL , CohenJA , ConfavreuxC , FoxEJ , et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease‐modifying therapy: a randomised controlled phase 3 trial. Lancet2012;380(9856):1829‐39. FernandezO , ArnoldD , CohenJ , ColesA , ConfavreuxC , FoxE , et al. Alemtuzumab improves disability by month 6 independent of relapse history in relapsing‐remitting multiple sclerosis patients: CARE‐MS II. Journal of Neurology2013;260:Suppl 14. FoxE , ArnoldD , CohenJ , ColesA , ConfavreuxC , HartungH , et al. Durable efficacy of alemtuzumab in relapsing‐remitting multiple sclerosis patients who participated in the CARE‐MS studies: three year follow‐up. Neurology2013;80:Suppl 7. GiovannoniG , ArnoldD , CohenJ , ColesA , ConfavreuxC , FoxE , et al. Disability improvement with alemtuzumab vs. interferon beta‐1a in relapsing‐remitting multiple sclerosis patients who experienced disease activity while on prior therapy (CARE‐MS II). Neurology2013;80:Suppl 7. HartungH , ArnoldD , CohenJ , ColesA , ConfavreuxC , FoxE , et al. Disability outcomes for alemtuzumab in RRMS patients who relapsed on prior therapy: CARE‐MS II. Journal of Neurology2012;259(1):Suppl 47‐8. HartungH , VollmerT , ArnoldD , CohenJ , ColesA , ConfavreuxC , et al. Alemtuzumab reduces ms disease activity in active relapsing‐remitting multiple sclerosis patients who had disease activity on prior therapy. Neurology2013;80:Suppl 7. ">CARE‐MS II</a>). In the alemtuzumab 12 mg comparison, there was a significant difference in favour of alemtuzumab at 24 and 36 months (RR 0.33, 95% CI 0.19 to 0.56). There was no significant heterogeneity (P = 0.50, I² = 0), so we applied the fixed‐effect model (<a href="./references#CD010968-fig-0015" title="">Analysis 7.1</a>). In the alemtuzumab 24 mg comparison, there was no significant difference in two groups (RR 0.34, 95% CI 0.10 to 1.16). There was significant heterogeneity (P = 0.14, I² = 55%), so we applied the random‐effect model (<a href="./references#CD010968-fig-0016" title="">Analysis 7.2</a>). </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD010968-sec-0079" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD010968-sec-0079"></div> <section id="CD010968-sec-0080"> <h3 class="title" id="CD010968-sec-0080">Summary of main results</h3> <p>Alemtuzumab was more effective than IFN beta 1a for the treatment of RRMS. This systematic review compared the benetif, tolerability and safety of alemtuzumab versus IFN beta 1a in the treatment of people with RRMS. Three RCTs involving 1694 participants contributed to the final analysis. In <a href="./references#CD010968-bbs2-0001" title="ButtonT , AltmannD , TozerD , DaltonC , CompstonD , MillerD , et al. Magnetisation transfer imaging of alemtuzumab treatment of multiple sclerosis. Multiple Sclerosis2013;19(2):241‐4. CAMMS223 Trial Investigators, ColesAJ , CompstonDA , SelmajKW , LakeSL , MoranS , MargolinDH , et al. Alemtuzumab vs. interferon beta‐1a in early multiple sclerosis. New England Journal of Medicine2008;359(17):1786‐801. ColesAJ , FoxE , VladicA , GazdaSK , BrinarV , SelmajKW , et al. Alemtuzumab more effective than interferon β‐1a at 5‐year follow‐up of CAMMS223 clinical trial. Neurology2012;78(14):1069‐78. ColesAJ , FoxE , VladicA , GazdaSK , BrinarV , SelmajKW , et al. Alemtuzumab versus interferon β‐1a in early relapsing‐remitting multiple sclerosis: post‐hoc and subset analyses of clinical efficacy outcomes. Lancet Neurology2011;10(4):338‐48. DanielsG , VladicA , BrinarV , ZavalishinI , ValenteW , OyuelaP , et al. Alemtuzumab‐related thyroid dysfunction in a phase 2 trial of patients with relapsing‐remitting multiple sclerosis. Journal of Clinical Endocrinology and Metabolism2014;99(1):80‐9. GravesJ , GalettaS , PalmerJ , MargolinD , RizzoM , BilbruckJ , et al. Alemtuzumab improves contrast sensitivity in patients with relapsing‐remitting multiple sclerosis. Multiple Sclerosis2013;19(10):1302‐9. ">CAMMS223 2008</a>, participants received either subcutaneous IFN beta 1a 44 μg three times per week or annual intravenous cycles of alemtuzumab at 12 mg per day or 24 mg per day for 36 months. In <a href="./references#CD010968-bbs2-0002" title="ArnoldD , BrinarV , CohenJ , ColesA , ConfavreuxC , FisherE , et al. Effect of alemtuzumab vs. Rebif (registered trademark) on brain MRI measurements: results of CARE‐MS I, a phase 3 study. Neurology2012; Vol. 78, issue 1:S11.006. BalcerL , ArnoldD , CohenJ , ColesA , ConfavreuxC , FoxE , et al. Alemtuzumab improves visual outcomes in treatment‐naive patients with relapsing‐remitting multiple sclerosis (RRMS): analysis from the phase 3 CARE‐MS I study. Journal of the Neurological Sciences2013;333:e375. CohenJA , ColesAJ , ArnoldDL , ConfavreuxC , FoxEJ , HartungHP , et al. Alemtuzumab versus interferon beta 1a as first‐line treatment for patients with relapsing‐remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet2012;380(9856):1819‐28. ColesA , BrinarV , ArnoldD , CohenJ , ConfavreauxC , FoxE , et al. Efficacy and safety results from CARE‐MS I: a phase 3 study comparing alemtuzumab and interferon‐(beta)‐1a. Multiple Sclerosis2011;17(10):Suppl 510. FoxE , ArnoldD , BrinarV , CohenJ , ColesA , ConfavreuxC , et al. Relapse outcomes with alemtuzumab vs. Rebif (registered trademark) in treatment‐naive relapsing‐remitting multiple sclerosis (CARE‐MS I): secondary and tertiary endpoints. Neurology2012;78(1):Suppl PD5.004. FoxE , ArnoldD , CohenJ , ColesA , ConfavreuxC , HartungH , et al. Durable efficacy of alemtuzumab in relapsing‐remitting multiple sclerosis patients who participated in the CARE‐MS studies: three year follow‐up. Neurology2013;80(7):Suppl 41.001. GiovannoniG , ArnoldD , CohenJ , ColesA , ConfavreuxC , FoxH , et al. Disease activity‐free status in comparison of alemtuzumab and Rebif (registered trademark) efficacy in multiple sclerosis I (CARE‐MS I) phase 3 study. Journal of Neurology2012;259(1):Suppl 47. ">CARE‐MS I</a> and <a href="./references#CD010968-bbs2-0003" title="ColesAJ , TwymanCL , ArnoldDL , CohenJA , ConfavreuxC , FoxEJ , et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease‐modifying therapy: a randomised controlled phase 3 trial. Lancet2012;380(9856):1829‐39. FernandezO , ArnoldD , CohenJ , ColesA , ConfavreuxC , FoxE , et al. Alemtuzumab improves disability by month 6 independent of relapse history in relapsing‐remitting multiple sclerosis patients: CARE‐MS II. Journal of Neurology2013;260:Suppl 14. FoxE , ArnoldD , CohenJ , ColesA , ConfavreuxC , HartungH , et al. Durable efficacy of alemtuzumab in relapsing‐remitting multiple sclerosis patients who participated in the CARE‐MS studies: three year follow‐up. Neurology2013;80:Suppl 7. GiovannoniG , ArnoldD , CohenJ , ColesA , ConfavreuxC , FoxE , et al. Disability improvement with alemtuzumab vs. interferon beta‐1a in relapsing‐remitting multiple sclerosis patients who experienced disease activity while on prior therapy (CARE‐MS II). Neurology2013;80:Suppl 7. HartungH , ArnoldD , CohenJ , ColesA , ConfavreuxC , FoxE , et al. Disability outcomes for alemtuzumab in RRMS patients who relapsed on prior therapy: CARE‐MS II. Journal of Neurology2012;259(1):Suppl 47‐8. HartungH , VollmerT , ArnoldD , CohenJ , ColesA , ConfavreuxC , et al. Alemtuzumab reduces ms disease activity in active relapsing‐remitting multiple sclerosis patients who had disease activity on prior therapy. Neurology2013;80:Suppl 7. ">CARE‐MS II</a>, participants received subcutaneous IFN beta 1a 44 μg three times per week or annual intravenous cycles of alemtuzumab 12 mg per day for 24 months. All three studies were at risk of performance bias and attrition bias, one study was 'unclear' risk in selection bias. In the alemtuzumab 12 mg comparison, the results showed statistically significant differences favouring alemtuzumab in reducing relapses, preventing disease progression and developing new T2 lesions on MRI after 24 and 36 months' follow‐up, but found no statistically significant difference in the changes of EDSS score. In the alemtuzumab 24 mg comparison, the results showed statistically significant differences favouring alemtuzumab in reducing relapses, preventing disease progression and the changes of EDSS score after 36 months' follow‐up. The rates of advese events were similarly high for both treatments, although the risk of discontinuations related to adverse effects was lower with alemtuzumab. However, considering that alemtuzumab is administered once per year, this could have an effect on the observation of adverse events. </p> </section> <section id="CD010968-sec-0081"> <h3 class="title" id="CD010968-sec-0081">Overall completeness and applicability of evidence</h3> <p>The review's aim was to compare the benefit, tolerability and safety of alemtuzumab versus interferon beta 1a in the treatment of people with RRMS to prevent disease activity. We included three studies involving 1694 participants. All three RCTs compared alemtuzumab versus subcutaneous interferon beta‐1a in participants with RRMS. alemtuzumab was given intravenously 12 mg per day or 24 mg per day on five consecutive days during the first month and on three consecutive days at months 12 and 24, while IFN beta 1a was given 44 μg subcutaneously three times weekly after dose titration. All three studies reported benefit as clinical relapses, disability worsening and changes of EDSS score. In addition, <a href="./references#CD010968-bbs2-0002" title="ArnoldD , BrinarV , CohenJ , ColesA , ConfavreuxC , FisherE , et al. Effect of alemtuzumab vs. Rebif (registered trademark) on brain MRI measurements: results of CARE‐MS I, a phase 3 study. Neurology2012; Vol. 78, issue 1:S11.006. BalcerL , ArnoldD , CohenJ , ColesA , ConfavreuxC , FoxE , et al. Alemtuzumab improves visual outcomes in treatment‐naive patients with relapsing‐remitting multiple sclerosis (RRMS): analysis from the phase 3 CARE‐MS I study. Journal of the Neurological Sciences2013;333:e375. CohenJA , ColesAJ , ArnoldDL , ConfavreuxC , FoxEJ , HartungHP , et al. Alemtuzumab versus interferon beta 1a as first‐line treatment for patients with relapsing‐remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet2012;380(9856):1819‐28. ColesA , BrinarV , ArnoldD , CohenJ , ConfavreauxC , FoxE , et al. Efficacy and safety results from CARE‐MS I: a phase 3 study comparing alemtuzumab and interferon‐(beta)‐1a. Multiple Sclerosis2011;17(10):Suppl 510. FoxE , ArnoldD , BrinarV , CohenJ , ColesA , ConfavreuxC , et al. Relapse outcomes with alemtuzumab vs. Rebif (registered trademark) in treatment‐naive relapsing‐remitting multiple sclerosis (CARE‐MS I): secondary and tertiary endpoints. Neurology2012;78(1):Suppl PD5.004. FoxE , ArnoldD , CohenJ , ColesA , ConfavreuxC , HartungH , et al. Durable efficacy of alemtuzumab in relapsing‐remitting multiple sclerosis patients who participated in the CARE‐MS studies: three year follow‐up. Neurology2013;80(7):Suppl 41.001. GiovannoniG , ArnoldD , CohenJ , ColesA , ConfavreuxC , FoxH , et al. Disease activity‐free status in comparison of alemtuzumab and Rebif (registered trademark) efficacy in multiple sclerosis I (CARE‐MS I) phase 3 study. Journal of Neurology2012;259(1):Suppl 47. ">CARE‐MS I</a> and <a href="./references#CD010968-bbs2-0003" title="ColesAJ , TwymanCL , ArnoldDL , CohenJA , ConfavreuxC , FoxEJ , et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease‐modifying therapy: a randomised controlled phase 3 trial. Lancet2012;380(9856):1829‐39. FernandezO , ArnoldD , CohenJ , ColesA , ConfavreuxC , FoxE , et al. Alemtuzumab improves disability by month 6 independent of relapse history in relapsing‐remitting multiple sclerosis patients: CARE‐MS II. Journal of Neurology2013;260:Suppl 14. FoxE , ArnoldD , CohenJ , ColesA , ConfavreuxC , HartungH , et al. Durable efficacy of alemtuzumab in relapsing‐remitting multiple sclerosis patients who participated in the CARE‐MS studies: three year follow‐up. Neurology2013;80:Suppl 7. GiovannoniG , ArnoldD , CohenJ , ColesA , ConfavreuxC , FoxE , et al. Disability improvement with alemtuzumab vs. interferon beta‐1a in relapsing‐remitting multiple sclerosis patients who experienced disease activity while on prior therapy (CARE‐MS II). Neurology2013;80:Suppl 7. HartungH , ArnoldD , CohenJ , ColesA , ConfavreuxC , FoxE , et al. Disability outcomes for alemtuzumab in RRMS patients who relapsed on prior therapy: CARE‐MS II. Journal of Neurology2012;259(1):Suppl 47‐8. HartungH , VollmerT , ArnoldD , CohenJ , ColesA , ConfavreuxC , et al. Alemtuzumab reduces ms disease activity in active relapsing‐remitting multiple sclerosis patients who had disease activity on prior therapy. Neurology2013;80:Suppl 7. ">CARE‐MS II</a> reported participants with new T2‐hyperintense lesions on MRI. There is low‐ to moderate‐quality evidence that annual intravenous cycles of alemtuzumab at a dose of 12 mg per day or 24 mg per day probably reduces the proportion of participants who experience relapse, and may reduce disability worsening and development of new T2 lesions on MRI over 2 to 3 years in comparison with subcutaneous IFN beta‐1a 44 μg three times per week. An average reduction of 0.8 EDSS units with alemtuzumab compared with interferon beta‐1a was observed at a dose of 24 mg per day in one study. All three trials reported adverse events and serious adverse events. The rates of adverse events were similarly high for both treatments, although the risk of discontinuations related to adverse effects was lower with alemtuzumab. In our view, this review has reliably compared the benetif, tolerability and safety of alemtuzumab versus interferon beta 1a. </p> </section> <section id="CD010968-sec-0082"> <h3 class="title" id="CD010968-sec-0082">Quality of the evidence</h3> <p>As presented in <a href="./full#CD010968-tbl-0001">summary of findings Table for the main comparison</a> and <a href="./full#CD010968-tbl-0002">summary of findings Table 2</a>, the quality of the body of evidence obtained for each outcome ranged from very low to moderate. All three studies were at high risk of performance bias and attrition bias, one study was 'unclear' risk in selection bias. There were a low number of events and a high heterogeneity in some outcomes. </p> </section> <section id="CD010968-sec-0083"> <h3 class="title" id="CD010968-sec-0083">Potential biases in the review process</h3> <p>An extensive and comprehensive search was undertaken to limit bias in the review process, however a low number of studies were retrieved. </p> <p>There were no potential biases from the review authors in the review process. In the development of this review, three review authors independently read and screened trials retrieved for inclusion, independently completed data extraction and assessed the quality of included trials to minimize potential biases. No conflict of interests were found in relation to the review authors of this review. </p> <p>The limitations of this review include:</p> <p> <ul id="CD010968-list-0011"> <li> <p>no assessment of publication bias through funnel plot analysis because there were only 3 studies. </p> </li> <li> <p>the lack of some outcome data in the included RCTs, for example, the data for benefit outcomes of alemtuzumab at a dose of 24 mg per day were not provided. </p> </li> </ul> </p> </section> <section id="CD010968-sec-0084"> <h3 class="title" id="CD010968-sec-0084">Agreements and disagreements with other studies or reviews</h3> <p>One systematic review included three studies in a qualitative synthesis and evaluated the effectiveness of alemtuzumab in the treatment of MS (<a href="./references#CD010968-bbs2-0035" title="RieraR , PorfírioGJ , TorloniMR . Alemtuzumab for multiple sclerosis. Cochrane Database of Systematic Reviews2016, Issue 4. [DOI: 10.1002/14651858.CD011203.pub2] ">Riera 2016</a>). The same studies were eligible for meta‐analyses in our current systematic review. There are subtle distinctions between the two reviews in the methods of meta‐analysis, but overall, our review achieved similar conclusions. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD010968-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010968.pub2/media/CDSR/CD010968/urn:x-wiley:14651858:media:CD010968:CD010968-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010968.pub2/media/CDSR/CD010968/image_t/tCD010968-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD010968-fig-0001" src="/cdsr/doi/10.1002/14651858.CD010968.pub2/media/CDSR/CD010968/image_n/nCD010968-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010968.pub2/full#CD010968-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010968.pub2/media/CDSR/CD010968/image_n/nCD010968-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010968-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010968.pub2/media/CDSR/CD010968/urn:x-wiley:14651858:media:CD010968:CD010968-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010968.pub2/media/CDSR/CD010968/image_t/tCD010968-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD010968-fig-0002" src="/cdsr/doi/10.1002/14651858.CD010968.pub2/media/CDSR/CD010968/image_n/nCD010968-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010968.pub2/full#CD010968-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010968.pub2/media/CDSR/CD010968/image_n/nCD010968-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010968-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010968.pub2/media/CDSR/CD010968/urn:x-wiley:14651858:media:CD010968:CD010968-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010968.pub2/media/CDSR/CD010968/image_t/tCD010968-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD010968-fig-0003" src="/cdsr/doi/10.1002/14651858.CD010968.pub2/media/CDSR/CD010968/image_n/nCD010968-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010968.pub2/full#CD010968-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010968.pub2/media/CDSR/CD010968/image_n/nCD010968-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010968-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010968.pub2/media/CDSR/CD010968/urn:x-wiley:14651858:media:CD010968:CD010968-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010968.pub2/media/CDSR/CD010968/image_t/tCD010968-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Number of participants experiencing at least one relapse at 24 and 36 months, Outcome 1 Alemtuzumab 12 mg vs interferon beta 1a." data-id="CD010968-fig-0004" src="/cdsr/doi/10.1002/14651858.CD010968.pub2/media/CDSR/CD010968/image_n/nCD010968-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Number of participants experiencing at least one relapse at 24 and 36 months, Outcome 1 Alemtuzumab 12 mg vs interferon beta 1a. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010968.pub2/references#CD010968-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010968.pub2/media/CDSR/CD010968/image_n/nCD010968-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010968-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010968.pub2/media/CDSR/CD010968/urn:x-wiley:14651858:media:CD010968:CD010968-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010968.pub2/media/CDSR/CD010968/image_t/tCD010968-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Number of participants experiencing at least one relapse at 24 and 36 months, Outcome 2 Alemtuzumab 24 mg vs interferon beta 1a." data-id="CD010968-fig-0005" src="/cdsr/doi/10.1002/14651858.CD010968.pub2/media/CDSR/CD010968/image_n/nCD010968-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Number of participants experiencing at least one relapse at 24 and 36 months, Outcome 2 Alemtuzumab 24 mg vs interferon beta 1a. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010968.pub2/references#CD010968-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010968.pub2/media/CDSR/CD010968/image_n/nCD010968-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010968-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010968.pub2/media/CDSR/CD010968/urn:x-wiley:14651858:media:CD010968:CD010968-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010968.pub2/media/CDSR/CD010968/image_t/tCD010968-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Number of participants whose disease progressed at 24 and 36 months, Outcome 1 Alemtuzumab 12 mg vs interferon beta 1a." data-id="CD010968-fig-0006" src="/cdsr/doi/10.1002/14651858.CD010968.pub2/media/CDSR/CD010968/image_n/nCD010968-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Number of participants whose disease progressed at 24 and 36 months, Outcome 1 Alemtuzumab 12 mg vs interferon beta 1a. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010968.pub2/references#CD010968-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010968.pub2/media/CDSR/CD010968/image_n/nCD010968-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010968-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010968.pub2/media/CDSR/CD010968/urn:x-wiley:14651858:media:CD010968:CD010968-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010968.pub2/media/CDSR/CD010968/image_t/tCD010968-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Number of participants whose disease progressed at 24 and 36 months, Outcome 2 Alemtuzumab 24 mg vs interferon beta 1a." data-id="CD010968-fig-0007" src="/cdsr/doi/10.1002/14651858.CD010968.pub2/media/CDSR/CD010968/image_n/nCD010968-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Number of participants whose disease progressed at 24 and 36 months, Outcome 2 Alemtuzumab 24 mg vs interferon beta 1a. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010968.pub2/references#CD010968-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010968.pub2/media/CDSR/CD010968/image_n/nCD010968-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010968-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010968.pub2/media/CDSR/CD010968/urn:x-wiley:14651858:media:CD010968:CD010968-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010968.pub2/media/CDSR/CD010968/image_t/tCD010968-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Number of participants with at least one adverse event at 24 and 36 months, Outcome 1 Alemtuzumab 12 mg vs interferon beta 1a." data-id="CD010968-fig-0008" src="/cdsr/doi/10.1002/14651858.CD010968.pub2/media/CDSR/CD010968/image_n/nCD010968-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Number of participants with at least one adverse event at 24 and 36 months, Outcome 1 Alemtuzumab 12 mg vs interferon beta 1a. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010968.pub2/references#CD010968-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010968.pub2/media/CDSR/CD010968/image_n/nCD010968-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010968-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010968.pub2/media/CDSR/CD010968/urn:x-wiley:14651858:media:CD010968:CD010968-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010968.pub2/media/CDSR/CD010968/image_t/tCD010968-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Number of participants with at least one adverse event at 24 and 36 months, Outcome 2 Alemtuzumab 24 mg vs interferon beta 1a." data-id="CD010968-fig-0009" src="/cdsr/doi/10.1002/14651858.CD010968.pub2/media/CDSR/CD010968/image_n/nCD010968-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 Number of participants with at least one adverse event at 24 and 36 months, Outcome 2 Alemtuzumab 24 mg vs interferon beta 1a. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010968.pub2/references#CD010968-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010968.pub2/media/CDSR/CD010968/image_n/nCD010968-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010968-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010968.pub2/media/CDSR/CD010968/urn:x-wiley:14651858:media:CD010968:CD010968-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010968.pub2/media/CDSR/CD010968/image_t/tCD010968-CMP-004-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Number of participants with severe adverse events at 24 and 36 months, Outcome 1 Alemtuzumab 12 mg vs interferon beta 1a." data-id="CD010968-fig-0010" src="/cdsr/doi/10.1002/14651858.CD010968.pub2/media/CDSR/CD010968/image_n/nCD010968-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 Number of participants with severe adverse events at 24 and 36 months, Outcome 1 Alemtuzumab 12 mg vs interferon beta 1a. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010968.pub2/references#CD010968-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010968.pub2/media/CDSR/CD010968/image_n/nCD010968-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010968-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010968.pub2/media/CDSR/CD010968/urn:x-wiley:14651858:media:CD010968:CD010968-CMP-004-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010968.pub2/media/CDSR/CD010968/image_t/tCD010968-CMP-004-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Number of participants with severe adverse events at 24 and 36 months, Outcome 2 Alemtuzumab 24 mg vs interferon beta 1a." data-id="CD010968-fig-0011" src="/cdsr/doi/10.1002/14651858.CD010968.pub2/media/CDSR/CD010968/image_n/nCD010968-CMP-004-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4 Number of participants with severe adverse events at 24 and 36 months, Outcome 2 Alemtuzumab 24 mg vs interferon beta 1a. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010968.pub2/references#CD010968-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010968.pub2/media/CDSR/CD010968/image_n/nCD010968-CMP-004-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010968-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010968.pub2/media/CDSR/CD010968/urn:x-wiley:14651858:media:CD010968:CD010968-CMP-005-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010968.pub2/media/CDSR/CD010968/image_t/tCD010968-CMP-005-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Mean Expanded Disability Status Scale score change from baseline at 24 and 36 months, Outcome 1 Alemtuzumab 12 mg vs interferon beta 1a." data-id="CD010968-fig-0012" src="/cdsr/doi/10.1002/14651858.CD010968.pub2/media/CDSR/CD010968/image_n/nCD010968-CMP-005-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5 Mean Expanded Disability Status Scale score change from baseline at 24 and 36 months, Outcome 1 Alemtuzumab 12 mg vs interferon beta 1a. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010968.pub2/references#CD010968-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010968.pub2/media/CDSR/CD010968/image_n/nCD010968-CMP-005-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010968-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010968.pub2/media/CDSR/CD010968/urn:x-wiley:14651858:media:CD010968:CD010968-CMP-005-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010968.pub2/media/CDSR/CD010968/image_t/tCD010968-CMP-005-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Mean Expanded Disability Status Scale score change from baseline at 24 and 36 months, Outcome 2 Alemtuzumab 24 mg vs interferon beta 1a." data-id="CD010968-fig-0013" src="/cdsr/doi/10.1002/14651858.CD010968.pub2/media/CDSR/CD010968/image_n/nCD010968-CMP-005-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5 Mean Expanded Disability Status Scale score change from baseline at 24 and 36 months, Outcome 2 Alemtuzumab 24 mg vs interferon beta 1a. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010968.pub2/references#CD010968-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010968.pub2/media/CDSR/CD010968/image_n/nCD010968-CMP-005-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010968-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010968.pub2/media/CDSR/CD010968/urn:x-wiley:14651858:media:CD010968:CD010968-CMP-006-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010968.pub2/media/CDSR/CD010968/image_t/tCD010968-CMP-006-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Number of participants with new T2‐hyperintense lesions on magnetic resonance imaging at 24 and 36 months, Outcome 1 Alemtuzumab 12 mg vs interferon beta 1a." data-id="CD010968-fig-0014" src="/cdsr/doi/10.1002/14651858.CD010968.pub2/media/CDSR/CD010968/image_n/nCD010968-CMP-006-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6 Number of participants with new T2‐hyperintense lesions on magnetic resonance imaging at 24 and 36 months, Outcome 1 Alemtuzumab 12 mg vs interferon beta 1a. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010968.pub2/references#CD010968-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010968.pub2/media/CDSR/CD010968/image_n/nCD010968-CMP-006-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010968-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010968.pub2/media/CDSR/CD010968/urn:x-wiley:14651858:media:CD010968:CD010968-CMP-007-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010968.pub2/media/CDSR/CD010968/image_t/tCD010968-CMP-007-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Number of participants experiencing treatment discontinuation caused by adverse events, Outcome 1 Alemtuzumab 12 mg vs interferon beta 1a." data-id="CD010968-fig-0015" src="/cdsr/doi/10.1002/14651858.CD010968.pub2/media/CDSR/CD010968/image_n/nCD010968-CMP-007-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.1</div> <div class="figure-caption"> <p>Comparison 7 Number of participants experiencing treatment discontinuation caused by adverse events, Outcome 1 Alemtuzumab 12 mg vs interferon beta 1a. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010968.pub2/references#CD010968-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010968.pub2/media/CDSR/CD010968/image_n/nCD010968-CMP-007-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010968-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010968.pub2/media/CDSR/CD010968/urn:x-wiley:14651858:media:CD010968:CD010968-CMP-007-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010968.pub2/media/CDSR/CD010968/image_t/tCD010968-CMP-007-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Number of participants experiencing treatment discontinuation caused by adverse events, Outcome 2 Alemtuzumab 24 mg vs interferon beta 1a." data-id="CD010968-fig-0016" src="/cdsr/doi/10.1002/14651858.CD010968.pub2/media/CDSR/CD010968/image_n/nCD010968-CMP-007-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.2</div> <div class="figure-caption"> <p>Comparison 7 Number of participants experiencing treatment discontinuation caused by adverse events, Outcome 2 Alemtuzumab 24 mg vs interferon beta 1a. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010968.pub2/references#CD010968-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010968.pub2/media/CDSR/CD010968/image_n/nCD010968-CMP-007-02.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD010968-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Alemtuzumab 12 mg compared to interferon beta 1a for relapsing‐remitting multiple sclerosis</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>alemtuzumab<b>12 mg compared to interferon beta 1a for relapsing‐remitting multiple sclerosis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with relapsing‐remitting multiple sclerosis<br/> <b>Settings:</b> <br/> <b>Intervention:</b> alemtuzumab 12 mg<br/> <b>Comparison:</b> interferon beta 1a </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Interferon beta 1a</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>alemtuzumab12 mg</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants experiencing at least one relapse</b><br/> Follow‐up: 24‐36 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>448 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>269 per 1000</b><br/> (233 to 314) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.6</b> <br/> (0.52 to 0.70) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1414<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants whose disability worsened</b><br/> Follow‐up: 24‐36 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>168 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>101 per 1000</b><br/> (76 to 133) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.6</b> <br/> (0.45 to 0.79) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1414<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1<b>,</b>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants with at least one adverse event</b><br/> Follow‐up: 24‐36 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>948 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>976 per 1000</b><br/> (929 to 1000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.03</b><br/> (0.98 to 1.08) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1415<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants with serious adverse events</b><br/> Follow‐up: 24‐36 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>192 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>197 per 1000</b><br/> (157 to 247) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.03</b> <br/> (0.82 to 1.29) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1415<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean Expanded Disability Status Scale score change from baseline</b> <br/> Follow‐up: 24‐36 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean EDSS score in the control groups ranged from <b>‐0.14 to 0.38</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean EDSS score in the intervention groups was <b>0.35 lower</b> (0.73 lower to 0.03 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1414<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants with new T2‐hyperintense lesions on magnetic resonance imaging</b><br/> Follow‐up: 24 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>630 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>472 per 1000</b><br/> (384 to 585) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.75</b><br/> (0.61 to 0.93) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1125<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants experiencing treatment discontinuation caused by adverse events</b><br/> Follow‐up: 24‐36 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>76 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>25 per 1000</b><br/> (14 to 43) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.33</b><br/> (0.19 to 0.56) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1414<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). The assumed risk in the comparison group is the median control group risk across studies. </p> <p>CI: Confidence interval; RR: Risk ratio.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded one level due to study limitation (blinding of participants and personnel could not be well performed). </p> <p><sup>2</sup> Downgraded for one level due to inconsistency (I<sup>2</sup> = 66%)<br/> <sup>3</sup> Downgraded for one level due to inconsistency (I<sup>2</sup> = 85%)<br/> <sup>4</sup> Downgraded one level due to inconsistency (high heterogeneity, I<sup>2</sup> = 88%)<br/> <sup>5</sup> Downgraded one level due to inconsistency (high heterogeneity, I<sup>2</sup> = 73%).<br/> <sup>6</sup>Downgraded one level due to imprecision (low number of events). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Alemtuzumab 12 mg compared to interferon beta 1a for relapsing‐remitting multiple sclerosis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010968.pub2/full#CD010968-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD010968-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Alemtuzumab 24 mg compared to interferon beta 1a for relapsing‐remitting multiple sclerosis</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>alemtuzumab<b>24 mg compared to interferon beta 1a for relapsing‐remitting multiple sclerosis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with relapsing‐remitting multiple sclerosis<br/> <b>Settings:</b> <br/> <b>Intervention:</b> alemtuzumab 24 mg<br/> <b>Comparison:</b> interferon beta 1a </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Interferon beta 1a</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>alemtuzumab24 mg</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants experiencing at least one relapse</b><br/> Follow‐up: 36 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>405 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>154 per 1000</b><br/> (93 to 251) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.38</b> <br/> (0.23 to 0.62) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>221<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single study estimate</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants whose disability worsened</b><br/> Follow‐up: 36 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>216 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>91 per 1000</b><br/> (45 to 182) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.42</b> <br/> (0.21 to 0.84) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>221<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single study estimate</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants with at least one adverse event</b><br/> Follow‐up: 24‐36 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>964 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>984 per 1000</b><br/> (926 to 1000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.02</b> <br/> (0.96 to 1.08) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>578<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants with serious adverse events</b><br/> Follow‐up: 24‐36 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>220 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>209 per 1000</b><br/> (154 to 288) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.95</b> <br/> (0.7 to 1.31) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>578<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean Expanded Disability Status Scale score change from baseline</b><br/> Follow‐up: 36 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean EDSS score in the control group was <b>0.38 higher</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean EDSS score in the intervention group was <b>0.45 lower</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>221<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single study estimate</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants experiencing treatment discontinuation caused by adverse events</b><br/> Follow‐up: 24‐36 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>89 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>30 per 1000</b><br/> (9 to 14) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.34</b> </p> <p>(0.10 to 1.16)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>593<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). The assumed risk in the comparison group is the median control group risk across studies. </p> <p>CI: Confidence interval; RR: Risk ratio.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded one level due to study limitation (blinding of participants and personnel could not be well performed). </p> <p><sup>2</sup> Downgraded one level due to imprecision (low number of events).<br/> <sup>3</sup> Downgraded one level due to inconsistency (high heterogeneity, I<sup>2</sup> = 86%.) </p> <p><sup>4</sup> Imprecision (‐2): In view of the low number of participants and the wide confidence intervals, we downgraded by two points. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Alemtuzumab 24 mg compared to interferon beta 1a for relapsing‐remitting multiple sclerosis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010968.pub2/full#CD010968-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010968-tbl-0003"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Number of participants experiencing at least one relapse at 24 and 36 months</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Alemtuzumab 12 mg vs interferon beta 1a <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1414</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [0.52, 0.70]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 At 24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1191</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.62 [0.53, 0.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 At 36 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>223</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.53 [0.35, 0.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Alemtuzumab 24 mg vs interferon beta 1a <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>221</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.38 [0.23, 0.62]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 At 36 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>221</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.38 [0.23, 0.62]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Number of participants experiencing at least one relapse at 24 and 36 months</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010968.pub2/references#CD010968-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010968-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Number of participants whose disease progressed at 24 and 36 months</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Alemtuzumab 12 mg vs interferon beta 1a <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1414</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [0.45, 0.79]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 At 24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1191</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.50, 0.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 At 36 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>223</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.16, 0.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Alemtuzumab 24 mg vs interferon beta 1a <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>221</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.42 [0.21, 0.84]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 At 36 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>221</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.42 [0.21, 0.84]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Number of participants whose disease progressed at 24 and 36 months</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010968.pub2/references#CD010968-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010968-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Number of participants with at least one adverse event at 24 and 36 months</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Alemtuzumab 12 mg vs interferon beta 1a <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1415</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.98, 1.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 At 24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [1.01, 1.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 At 36 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>215</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [0.98, 1.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Alemtuzumab 24 mg vs interferon beta 1a <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>578</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.96, 1.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 At 24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>363</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [1.01, 1.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 At 36 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>215</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.97, 1.02]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Number of participants with at least one adverse event at 24 and 36 months</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010968.pub2/references#CD010968-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010968-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Number of participants with severe adverse events at 24 and 36 months</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Alemtuzumab 12 mg vs interferon beta 1a <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1415</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.82, 1.29]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 At 24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.81, 1.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 At 36 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>215</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.60, 1.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Alemtuzumab 24 mg vs interferon beta 1a <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>578</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.70, 1.31]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 At 24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>363</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.56, 1.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 At 36 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>215</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [0.69, 1.80]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Number of participants with severe adverse events at 24 and 36 months</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010968.pub2/references#CD010968-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010968-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Mean Expanded Disability Status Scale score change from baseline at 24 and 36 months</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Alemtuzumab 12 mg vs interferon beta 1a <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1414</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.35 [‐0.73, 0.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 At 24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1191</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.20 [‐0.60, 0.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 At 36 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>223</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.7 [‐1.04, ‐0.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Alemtuzumab 24 mg vs interferon beta 1a <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>221</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.83 [‐1.17, ‐0.49]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 At 36 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>221</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.83 [‐1.17, ‐0.49]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Mean Expanded Disability Status Scale score change from baseline at 24 and 36 months</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010968.pub2/references#CD010968-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010968-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Number of participants with new T2‐hyperintense lesions on magnetic resonance imaging at 24 and 36 months</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Alemtuzumab 12 mg vs interferon beta 1a <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.61, 0.93]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 At 24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.61, 0.93]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Number of participants with new T2‐hyperintense lesions on magnetic resonance imaging at 24 and 36 months</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010968.pub2/references#CD010968-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010968-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Number of participants experiencing treatment discontinuation caused by adverse events</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Alemtuzumab 12 mg vs interferon beta 1a <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1414</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.19, 0.56]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 At 24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1191</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.37 [0.20, 0.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 At 36 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>223</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.23 [0.07, 0.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Alemtuzumab 24 mg vs interferon beta 1a <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>593</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.34 [0.10, 1.16]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 At 24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>372</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.55 [0.23, 1.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 At 36 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>221</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.16 [0.04, 0.67]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Number of participants experiencing treatment discontinuation caused by adverse events</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010968.pub2/references#CD010968-tbl-0009">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD010968.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD010968-note-0004">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD010968-note-0003">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD010968-note-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD010968-note-0002">Français</a> </li> <li class="section-language"> <a class="" href="ms#CD010968-note-0005">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD010968-note-0001">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010968\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010968\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010968\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010968\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010968\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010968\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010968\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010968\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010968\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010968\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010968\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010968\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010968\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010968\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010968\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010968\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010968\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010968\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=urvLIhM4&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010968.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD010968.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD010968.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD010968.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010968.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740724668243"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD010968.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740724668247"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD010968.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e6872feee1c00',t:'MTc0MDcyNDY2OC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 